Introduction {#Sec1}
============

The market for peptide based therapeutics has been constantly growing since the late 1990s with 140 peptide drugs currently estimated to be undergoing clinical trials and 500 therapeutic peptides in pre-clinical development (Fosgerau and Hoffmann [@CR57]; Kaspar and Reichert [@CR104]; Otvos and Wade [@CR153]). Biologically active peptides are excellent drug candidates due to high receptor selectivity, binding affinity, potency and relatively low toxicity (Fosgerau and Hoffmann [@CR57]; Trabocchi and Guarna [@CR198]). However, the therapeutic potential of peptides can be limited due to their poor chemical and physical stability, short plasma half-life, and low oral bioavailability (Fosgerau and Hoffmann [@CR57]; Trabocchi and Guarna [@CR198]). Peptide drug delivery to the site of action is often challenging and improved technologies to overcome this obstacle are highly desirable (Lewis and Richard [@CR121]). Structural and functional modifications of native peptides using chemical techniques have been used to generate compounds with higher affinity, improved enzymatic stability and/or efficacy compared to the parent peptide (Trabocchi and Guarna [@CR198]). Peptide backbone modifications, cyclization, unnatural amino acid insertion, PEGylation, glycosylation, phosphorylation and lipidation are common techniques to improve the physicochemical and pharmacological profiles of bioactive peptides. (Zhang and Bulaj [@CR233])

Peptide lipidation is an effective strategy to modify the pharmacokinetic and pharmacodynamic properties of lead peptide therapeutics and has proven to be successful with several marketed peptides including liraglutide (Victoza^®^) (Jackson et al. [@CR95]; Knudsen et al. [@CR107]) and insulin detemir (Levemir^®^) (Zhang and Bulaj [@CR233]; Home and Kurtzhals [@CR85]; Le Floch [@CR117]). Incorporation of lipid units onto a peptide backbone can dramatically increase enzymatic stability (Simerska et al. [@CR183]), receptor selectivity and potency (Ward et al. [@CR206]), bioavailability (Hamman et al. [@CR71]; Park et al. [@CR154]; Renukuntla et al. [@CR165]; Karsdal et al. [@CR103]) and drug delivery potential (membrane permeability) (Zhang and Bulaj [@CR233]; Simerska et al. [@CR183]).

This review describes the impact of lipidation on peptide-based drug development and summarises the most recent strategies to incorporate a lipid moiety onto a peptide using chemical techniques. A brief discussion on naturally occuring lipidated proteins and peptides and the potential for lipidation to create bioactive therapeutics is covered. The highlight of this perspective relates to synthetic approaches to incorporate Pam~n~Cys-based Toll-like receptor 2 (TLR2) lipidated ligands into peptides with the potential to generate self-adjuvanting vaccine constructs.

Protein Lipidation in Nature {#Sec2}
----------------------------

Protein lipidation is one of the most important post- and co-translational modifications controlling protein affinity to cellular membranes and influencing protein regulatory and signalling functions (Mejuch and Waldmann [@CR139]; Resh [@CR167]). Altered lipidation patterns are associated with various diseases including cancer, neurological diseases, diabetes, infections (bacterial, fungal and viral) (Resh [@CR166]).

Protein acylation phenomena encompasses a broad range of saturated and unsaturated fatty acids of different length creating proteins with a unique set of functions. Protein-bound lipid types and lipid-protein linkages vary in nature. Covalent attachment of unique fatty acid chains is controlled by the action of specific transferases affording a broad range of lipidated proteins including *N*-myristoylated, *S*- or *N*-palmitoylated, and cholesterol- and isoprenol-enriched moieties (Fig. [9.1](#Fig1){ref-type="fig"}). Glycosylphosphatidylinositol (GPI), and phosphatidylethanolamine (PE) conjugation to proteins has also been described (Resh [@CR167]).Fig. 9.1Protein modifications with various lipids found in nature

Lipid addition occurs at *N*- and *C*- terminal sites of proteins or within the protein sequence directed by specific amino acids such as cysteine, serine, threonine, and lysine (Hannoush [@CR73]). Lipidation can be irreversible when formed *via* an amide bond using an *N*-terminal glycine or cysteine moiety (*N*-myristoylation and *N*- palmitoylation, respectively) or reversible when a thioester bond is formed between the fatty acid the thiol of the cysteine residue (*S*-palmitoylation), Fig. [9.1](#Fig1){ref-type="fig"} (Resh [@CR167]; Chamberlain and Shipston [@CR31]).

Proteins can exist in a mono-lipidated state or with multiple-lipid group addition. Membrane proteins such as MARCKS, GPCRs, and K-Ras4B are monolipidated proteins enriched with myristoyl, palmitoyl and farnesyl motifs, respectively. The Hedgehog (Hh) family of proteins which are associated with developmental processes (Lee et al. [@CR120]) are modified with palmitate and cholesterol; similarly, the Src family kinases are myristoylated and palmitoylated and plasma membrane H-Ras and N-Ras proteins are farnesylated and palmitoylated (Resh [@CR167]).

Irreversible protein modification with myristic acid, a 14-carbon fatty acid, is the most prevalent in nature and accounts for 0.5--0.8% of all lipidated eukaryotic proteins. It can occur both co- and post-translationally at the *N*-terminal glycine and is catalysed by *N*-myristoyltransferase (NMT), Fig. [9.1a](#Fig1){ref-type="fig"} (Resh [@CR167]; Wright et al. [@CR215]; Resh [@CR168]). *N*-Myristoylation at the *N*ε of lysine was also observed for interleukin 1α (Stevenson et al. [@CR189]) and tumour necrosis factor alpha (TNF) (Stevenson et al. [@CR188]); However, enzymes involved in these acylation processes are yet to be identified (Resh [@CR168]). *N*-Myristoylated proteins such as c-Src, BID, PAK2, or gelsolin play important roles in various biological processes including cellular transformation and effecting protein localization (Hannoush [@CR73]; Wright et al. [@CR215]). *N*-Myristoylation is involved in pathogen survival and altered myristoylation patterns are linked to carcinogenesis (Wright et al. [@CR215]).

*S*- Palmitoylation is the most common form of protein *S*-acylation affording reversibly-tagged proteins with a 16-carbon palmitic acid unit (Chamberlain and Shipston [@CR31]; Resh [@CR168]). *S*-Palmitoylation can occur at the cysteine moiety located in the proximity of either the *N* -or *C*-terminus of proteins, Fig. [9.1b](#Fig1){ref-type="fig"}. Attachment of stearic acid (C18:0) and monounsaturated omega-9 oleic acid (C18:1) *via* the thiol group of a cysteine residue has also been described (Chamberlain and Shipston [@CR31]).

Due to labile nature of the thioester bond used to link a fatty acid with a protein backbone, a dynamic equilibrium between protein *S*-acylation and deacylation with distinct turnover rates occurs that influences intracellular localization, membrane association, and the regulatory functions of a diverse family of proteins. *S*-Acylation of cellular proteins is mediated *via S*-acyl transferases from the zDHHC protein family. However, only scant information is available on the *S*-acyl thioesterases involved in protein deacetylation and the dynamic *S*-acylation process (Chamberlain and Shipston [@CR31]). It is proposed that enzymes from the serine hydrolase family including acyl protein thioesterases (APTs) (Davda and Martin [@CR43]), and protein palmitoyl thioesterases (PPTs) (Lin and Conibear [@CR123]) may be involved (Chamberlain and Shipston [@CR31]).

*S*-Acylation facilitates stable membrane binding of peripheral proteins and mediates protein targeting to specific endoplasmic reticulum (ER) subdomains. Protein *S*-acylation controls trafficking and localization of cellular proteins, and improves protein stability in addition to regulating cellular signalling receptors (Chamberlain and Shipston [@CR31]).

The Hedgehog protein family are critical proteins with roles in embryonic development and tumorigenesis (Resh [@CR168]; Pepinsky et al. [@CR157]). These mature signalling proteins are dually lipidated comprising a palmitate unit which is incorporated through an amide bond at *N*-terminal cysteine (*N*-palmitoylation) *via* the action of hedgehog acyltransferase (Hhat), a member of a membrane-bound *O*-acyltransferases (MBOAT) protein superfamily (Konitsiotis et al. [@CR110]; Matevossian and Resh [@CR134]), and a cholesterol moiety covalently attached to the *C*-terminal glycine *via* its 3β-hydroxyl group, Fig. [9.1c](#Fig1){ref-type="fig"} (Resh [@CR167], [@CR168]). *N*- Palmitoylation is essential for signalling activity of Hh proteins during development while the cholesterol unit aids the signalling functions (Resh [@CR167], [@CR168]). Aberrant Hh signalling pathways result in birth defects in humans including microencephaly, cyclopia, absent nose or cleft palate. The development of breast, prostate and lung cancer has also been associated with Hh signaling anomalies (Gupta et al. [@CR68]).

Another member of MBOAT superfamily is porcupine (Porcn) transferase which mediates attachment of a monounsaturated *cis*-Δ9-palmitoleate unit *via* a side chain of serine residue to a secreted Wnt glycoprotein family (Resh [@CR168]; Hofmann [@CR84]; Nile and Hannoush [@CR151]; Shindou et al. [@CR182]). This post-translational lipid attachment plays a crucial role in regulating signalling during embryonic development and tissue homeostasis, Fig. [9.1d](#Fig1){ref-type="fig"} (Resh [@CR168]; Nile and Hannoush [@CR151]). It has been recently reported that Wnts palmitoylation is reversible; notum hydrolase, which participates in deacylation, affords an inactive form of Wnts with inhibited signalling ability (Resh [@CR168]; Nile and Hannoush [@CR151]; Zhang et al. [@CR236]; Kakugawa et al. [@CR100]). Targeting Wnt signalling pathways using synthetic modulators including small molecules and peptides is therefore a promising tool to inhibit Wnt-driven diseases such as cancer (Nile and Hannoush [@CR151]; Anastas and Moon [@CR3]).

Ghrelin *O*-acyltransferase (GOAT), another MBOAT enzyme, mediates the covalent attachment of octanoic acid onto Ser-3 of the 28-amino acid peptide hormone ghrelin (Fig. [9.1e](#Fig1){ref-type="fig"}) (Resh [@CR168]; Yang et al. [@CR220]; Gutierrez et al. [@CR69]; Kojima et al. [@CR109]; Müller et al. [@CR148]). Ghrelin octanoylation is essential for the secretion of insulin and growth hormone, and hormone activity including appetite stimulation, adiposity and cardiovascular functions (Resh [@CR168]; Gutierrez et al. [@CR69]; Müller et al. [@CR148]; Sato et al. [@CR179]). Therefore, ghrelin is an attractive target in novel therapies to treat obesity and diabetes (Müller et al. [@CR148]; Sato et al. [@CR179]).

Protein prenylation refers to a post-translational attachment of isoprenoid lipids. Incorporation of farnesyl (C15) and geranylgeranyl (C20) groups is effected by formation of a thioether bond using a cysteine moiety in the *C*-terminal proximity of the protein *via* protein farnesyltransferase (FT) and geranylgeranyltransferase 1 (GGT 1), Fig. [9.1f](#Fig1){ref-type="fig"}, g, respectively (Wang and Casey [@CR201]). The fully processed lipidated protein contains a prenylated cysteine residue with a methylated carboxylic acid moiety, at the protein *C*-terminus. Members from HRAS, KRAS, NRAS, prelamin A, lamin B, and RAS-related GTPases are examples of protein families incorporating isoprenoid lipids within their structures (Wang and Casey [@CR201]). Prenylation controls the oncogenic activity of many proteins including farnesylated RAS proteins that are involved in 30% of human cancers (Wang and Casey [@CR201]).

Another common eukaryotic post-translational lipid modification is the attachment of a complex glycosylphosphatidylinositol anchor to the *C*-terminus of proteins (Paulick and Bertozzi [@CR156]; Ferguson et al. [@CR55]). GPI comprises a phosphoethanolamine linker, a highly conserved glycan core (mannose(α1-2)mannose(α1-6)mannose(α1-4)glucosamine(α1-6)*myo*-inositol) and phospholipid tail which links the GPI anchor to the cell membrane (Paulick and Bertozzi [@CR156]; Ferguson et al. [@CR55]). The sugar-rich domain can be further modified with the addition of various groups including other glycans, sialic acid and phosphoethanolamine moieties affording functionally diverse glycoforms of GPI anchors (Paulick and Bertozzi [@CR156]; Ferguson et al. [@CR55]). The lipid portion of the GPI moiety differs depending on the protein which it is attached to and the organism it originates from. The GPI anchor of human erythrocyte acetylcholinesterase for example, comprises three fatty acids in various states of saturation and lengths ranging from 16 to 22 carbons (Fig. [9.2](#Fig2){ref-type="fig"}) (Paulick and Bertozzi [@CR156]; Ferguson et al. [@CR55]; Deeg et al. [@CR46]; Roberts et al. [@CR171], [@CR170]). The exact structure-activity relationship of GPI-anchored proteins is poorly understood due to the complex nature of the GPI anchor structure. GPI-anchored proteins are multifunctional; these proteins have been identified in receptors, hydrolytic enzymes, adhesion and regulatory molecules etc (Paulick and Bertozzi [@CR156]; Ferguson et al. [@CR55]).Fig. 9.2Chemical structure of GPI anchor of human erythrocyte acetylcholinesterase (Paulick and Bertozzi [@CR156]; Ferguson et al. [@CR55]; Deeg et al. [@CR46]; Roberts et al. [@CR170], [@CR171])

Atg8 and LC3 proteins found in yeast and mammals respectively, contain a phospholipid moiety, namely phosphatidylethanolamine (PE) that is post-translationally anchored to a *C*-terminal glycine residue *via* numerous steps of ubiquitination-like reactions catalysed by autophagy-related (Atg) proteins (Resh [@CR167]). It has been reported that increased levels of PE enhance autophagy, a cytoprotective mechanism responsible for degradation of toxic proteins and potentially harmful and damaged organelles (Feng et al. [@CR54]; Rockenfeller et al. [@CR173]). Modulating autophagy can be used for the treatment of human disorders including cancer, diabetes, and Alzheimer's and Parkinsons' disease therefore new autophagy controllers are strongly desirable (Feng et al. [@CR54]; Rockenfeller et al. [@CR173]).

In summary, regulating the action of lipidated proteins may lead to potential therapies to treat infectious disease and human pathologies. Targeting NMT, Hedgehog acyltransferase, FT and GGT 1 inhibitors may play a role in anticancer therapies (Wang and Casey [@CR201]; Berndt et al. [@CR14]). Effective techniques to modulate prenylation patterns can be used in hepatitis D and C viruses (HDV and HCV) treatment (Koh et al. [@CR108]; Cory et al. [@CR42]; Ye et al. [@CR223]), premature ageing disorders such as Hutchinson-Gilford progeria syndrome (HGPS) (Gordon et al. [@CR64]; Young et al. [@CR226]) in addition to neurodegenerative pathologies like multiple sclerosis and Alzheimer's disease (Wang and Casey [@CR201]; Gao et al. [@CR60]).

Nature-Derived Lipopeptides with Therapeutic Potential {#Sec3}
------------------------------------------------------

Lipopeptides isolated from microorganisms such as fungi and bacteria show great therapeutic promise in the development of novel antimicrobial (Cochrane and Vederas [@CR40]), antifungal, antitumor, and anti-inflammatory agents. In case of the plipastatins they can also act as potential therapies for neurological diseases (Dey et al. [@CR48]).

*Bacillus* and *Paenibacillus* spp. produce lipopeptides of various structures including cyclic cationic and non-cationic lipopeptides where ring formation mostly occurs *via* the ester or amide bond and engages the *C*-terminal carboxylic acid residue (Cochrane and Vederas [@CR40]). The presence of both, [d]{.smallcaps}- and [l]{.smallcaps}-amino acids together with non-natural amino acids in these lipopeptide sequences is common and improves peptide stability against enzymatic degradation. Branched saturated or unsaturated fatty acids with diverse structures with the main chain varying mostly between C11 to 14 carbons are mostly incorporated into the *N*α-terminal side of the peptides and often feature a β-hydroxyl moiety in their structure (Cochrane and Vederas [@CR40]; Jacques [@CR96]).

Polymyxins, octapeptins, pelgipeptins, and paenibacterins exhibit non-proteinogenic 2,4-diaminobutyric acid (Dab) residues that amplify the cationic character of these peptides (Cochrane and Vederas [@CR40]). Examples of non-cationic cyclic lipopeptides include the iturin-, surfactin-, fengycin-, fusaricidin-, marihysin-, and kurstakin-families (Fig. [9.3](#Fig3){ref-type="fig"}) (Cochrane and Vederas [@CR40]).Fig. 9.3Selected examples of chemical structures of lipopeptides isolated from *Bacillus* and *Paenibacillus* spp (Cochrane and Vederas [@CR40]; Jacques [@CR96])

Linear cationic lipopeptides derived from *Bacillus* and *Paenibacillus* spp. such as cerexins and tridecaptins display promising antibacterial activity against Gram-positive and Gram-negative microbes (Fig. [9.3](#Fig3){ref-type="fig"}). A more detailed description of exact structures and biological activities for *Bacillus* and *Pseudomonas* spp. derived lipopeptides has recently been published (Cochrane and Vederas [@CR40]; Jacques [@CR96]; Mnif and Ghribi [@CR143]).

Lipopeptides isolated from *Pseudomonas* spp., which mainly include the viscosins, amphisins and tolaasins in addition to syringomycins, are mostly known for their antiviral and antimicrobial properties (Mnif and Ghribi [@CR143]; Raaijmakers et al. [@CR159]). These structurally diverse cyclic peptides differ in the chain length and comprise 9-25 residues in the form of natural and non-natural amino acids including *allo*-threonine (*allo*-Thr), *allo*-isoleucine (*allo*-Ile), 3-hydroxyaspartic acid, Dab and homoserine (Hse). 4-Chlorothreonine is the amino acid responsible for the antifungal activity of syringomycin (Fig. [9.4](#Fig4){ref-type="fig"}) (Grgurina et al. [@CR67]). The fatty acid moiety attached to the *N*-terminus of the peptide chain varies in length and composition and, similar to *Bacillus*-derived peptides, often features the β-hydroxyl unit. The lactone ring is generally formed between the carboxylic acid of the *C*-terminal amino acid and the hydroxyl group of either Ser, Thr or *allo*-Thr present within the peptide chain (Mnif and Ghribi [@CR143]; Raaijmakers et al. [@CR159]).Fig. 9.4Chemical structures of non-natural amino acids found in lipopeptides isolated from *Pseudomonas* spp.

Other microbial sources of biologically active lipidated peptides with promising therapeutic potential found in nature include strains of *Acremonium*, *Streptomyces*, and *Actinoplanes* (Mnif and Ghribi [@CR143]).

Lipopeptides exhibit a broad spectrum of activities against many pathogens and some naturally-derived compounds, as in the case of daptomycin, polymyxin B or colistin, have already received the Food and Drug Administration (FDA) approval. Daptomycin (Cubicin) isolated from *Streptomyces roseosporus* is a 13-amino acid, cyclic lipopeptide, containing decanoic acid at the *N*α-amino group of the *N*-terminal [l]{.smallcaps}-tryptophan. Daptomycin exhibits potent activity against Gram-positive pathogens (Fig. [9.5](#Fig5){ref-type="fig"}) (Debono et al. [@CR45]; Vilhena and Bettencourt [@CR200]).Fig. 9.5Chemical structure of daptomycin (cubicin)

Polymyxins are mixed peptide antibiotics produced by *Bacillus polymyxa* and are considered to be the last-line of defence agents against Gram-negative organisms; their use is limited due to concerns with nephrotoxicity (Stansly and Schlosser [@CR186]; Benedict and Langlykke [@CR13]). The general structure of polymyxins comprises a cyclic heptapeptide core attached to a tripeptide unit containing a lipid portion at the *N*α-terminal site of the linear fragment (Velkov et al. [@CR199]). Polymyxins are mixtures of structurally similar peptides. Members of the polymyxin B family mostly differ in the fatty acid component of the antibiotics. Examples include (*S*)-6-methylheptanoic acid for polymyxin B~1~ and B~2~ respectively (Velkov et al. [@CR199]; Orwa et al. [@CR152]). Colistin A and colistin B are highlighted examples of the polymyxin E family; these antibiotics differ in the substitution of [d]{.smallcaps}-phenylalanine to [d]{.smallcaps}-leucine at position six of polymyxin B (Fig. [9.6](#Fig6){ref-type="fig"}) (Velkov et al. [@CR199]; Brink et al. [@CR19]).Fig. 9.6Chemical structure of polymyxin B1, B2 and colistin A and B

The concept of protein lipidation is clearly not uncommon in nature hence application of this strategy to the therapeutic arena offers enormous potential for the generation of effective peptide-based drug candidates. Therefore, development and synthetic optimisation of naturally derived lipopeptides may afford fine-tuned therapeutics, which are less toxic, more potent and capable of treating multidrug-resistant infections. Interestingly, it has been reported that the attachment of aliphatic chains of various length (C12-C16) can modulate antimicrobial and antifungal activity of otherwise inert short peptides (Makovitzki et al. [@CR129]). Therefore, peptide lipidation can be used as an effective strategy to generate peptide drug leads with clinical potential.

Peptide Lipidation to Generate Peptide-Based Therapeutics {#Sec4}
---------------------------------------------------------

Peptide lipidation can modulate the physicochemical and pharmacological properties of bioactive peptides generating therapeutically useful targets. Increased lipophilicity of peptides due to the presence of fatty acids affects the secondary structure and receptor and membrane binding characteristics of peptides; accordingly lipidation alters absorption, distribution, metabolism, and excretion (ADME) properties and therefore is an attractive tool to convert peptides into drug candidates (Zhang and Bulaj [@CR233]). The most notable examples of clinically relevant lipidated peptides include long-acting insulin detemir (Levemir^®^) (Home and Kurtzhals [@CR85]; Le Floch [@CR117]) and liraglutide (Victoza^®^) (Jackson et al. [@CR95]; Knudsen et al. [@CR107]), a glucagon-like peptide-1 (GLP-1) receptor agonist, which are both used to treat diabetes (Fig. [9.7](#Fig7){ref-type="fig"}).Fig. 9.7Primary sequence of GLP1(7-37), liraglutide and insulin detemir

The prolonged activity of insulin detemir is due to the presence of C14 myristic acid incorporated into lysine-29 of the B chain of a modified insulin peptide sequence where the threonine-30 residue was removed (Fig. [9.7](#Fig7){ref-type="fig"}) (Le Floch [@CR117]; Kurtzhals [@CR114]).

Liraglutide is a long-acting analogue of GLP-1(7-37) where Lys-34 was replaced with Arg and Lys-26 was acylated with a C16 fatty acid attached to γ-glutamic acid as a spacer. The palmitic acid moiety plays a crucial role in delaying liraglutide absorption and extending the half-life of the drug which has been estimated to be 13 hours after subcutaneous injection compared to approximately 2 minutes for the native GLP-1 (Rigato and Fadini [@CR169]; Elbrond et al. [@CR52]). In addition, renal clearance of the drug is reduced due to the shielding effect of the fatty acid moiety; liraglutide binds to plasma albumin *via* the fatty acid group preventing drug degradation by dipeptidyl peptidase-4 (DPP-4) (Malm-Erjefalt et al. [@CR132]; Watson et al. [@CR207]). Lipidation of potent, but unstable GLP-1(7-37), much improved the pharmacokinetic profile of the peptide making it suitable for once-daily administration (Elbrond et al. [@CR52]; Ryan and Hardy [@CR175]). Liraglutide (Saxenda^®^) has been recently approved by the FDA and the European Medicines Agency (EMA) for adjunctive treatment of obesity (December 2014 and March 2015, respectively) (Iepsen et al. [@CR89]; Bray [@CR16]; Tomlinson et al. [@CR195]).

It has been reported that the type and composition of the fatty acid attached to a bioactive peptide as well as the nature of the spacer between the peptide chain and the fatty acid moiety influences its activity and plasma half-life (Knudsen et al. [@CR107]; Madsen et al. [@CR128]; Lau et al. [@CR116]).

Structure-activity studies of liraglutide analogues revealed the importance of the length, composition, polarity and bulkiness of the fatty acid moiety as well as the type of spacer between the active molecule and the lipid tail on half-life calculations (*in vivo* in pigs) and potency using the cloned human GLP-1 model (Knudsen et al. [@CR107]; Madsen et al. [@CR128]). Linear fatty acids ranging from C10 to C18 (**1**) incorporated into the liraglutide sequence using various linkers including α-, [d]{.smallcaps}-γ-glutamic acid, 4-aminobutanoic acid (GABA), β-alanine and triethyleneglycol were evaluated (Fig. [9.8a](#Fig8){ref-type="fig"}) (Madsen et al. [@CR128]). Interestingly, prolonged activity increased with the fatty acid chain length starting from 0.8 hours for C10, increasing to 5.1 h (C11), 7.6 (C12), 9 h (C14), 16 h (C16) and 21 h (C18); receptor potency was only affected when the acid chain length was longer than 16 carbons (Madsen et al. [@CR128]). The study underlined the importance of the spacer between the active peptide and the fatty acid and revealed the complete loss of receptor potency when palmitic acid was directly bound to Lys-26 (Madsen et al. [@CR128]). Liraglutide analogues containing α- or [d]{.smallcaps}-γ-glutamic acid (**2** and **3**), GABA (**4**) or β-Ala (**5**), as linkers in place of the native γ-Glu demonstrated similar activities and half-life values to those of liraglutide; unlike the triethylene glycol linker (**6**) which caused a 25-fold decrease in activity (Fig. [9.8b](#Fig8){ref-type="fig"}) (Knudsen et al. [@CR107]; Madsen et al. [@CR128]). Increasing the polarity of the fatty acid component by introducing one or more ether groups (**7-9**) or inserting hydroxyl group at the omega terminus (**10**) decreased the protraction of the analogues possibly due to reduced interactions with the fatty acid sites present on albumin, Fig. [9.8c](#Fig8){ref-type="fig"} (Madsen et al. [@CR128]). Modification of the C16 palmitic acid in the liraglutide sequence with 2-hexyldecanoyl acid (**11**) which is equivalent to 16 carbon atoms led to slightly improved protraction (18 hours versus 16 h) and a significant decrease in potency of the analogue. Incorporation of more bulky phenyl- and cyclohexyl rings (**12** and **13**, respectively) in place of palmitate, or palmitate replacement with a pentylbenzenesulfonyl group (**14**) was not beneficial in regards to improved potency and half-life values compared to the original molecule (Fig. [9.8d](#Fig8){ref-type="fig"}) (Madsen et al. [@CR128]).Fig. 9.8Selected modifications of an acyl component (**a**, **c**, **d**) and spacer (**b**) investigated during the structure-activity study on liraglutide (Madsen et al. [@CR128])

Further derivatization of the liraglutide structure resulted in the development of semaglutide (Lau et al. [@CR116]; Nauck et al. [@CR150]). Semaglutide is the once-weekly GLP-1(7-37) analogue currently in phase 3 clinical development for the treatment of type 2 diabetes (Lau et al. [@CR116]; Nauck et al. [@CR150]). Extending the half-life of semaglutide to 165 hours was realised through systematic study of the fatty acid chain type and the spacer attached to liraglutide (Lau et al. [@CR116]). The superior effect of a C18 octadecanedioic acid moiety attached to Lys-26 and a long spacer unit composed of γ-Glu attached to two 8-amino-3,6-dioxaoctanoic acid moieties provided the optimal lead candidate (Fig. [9.9](#Fig9){ref-type="fig"}). Non-natural modification of Ala-8 with 2-aminoisobutyric acid (Aib) allowed for additional shielding of the molecule from degradative DPP-4 action (Lau et al. [@CR116]).Fig. 9.9Primary sequence of semaglutide

The therapeutic potential of peptides as drugs is often hampered by undesirable ADME profiles; peptides are subjected to rapid proteolytic cleavage in the digestive system and are unable to cross the epithelial layer (Karsdal et al. [@CR103]; Di [@CR49]). Oral administration of peptide-based therapeutics is therefore limited. Many strategies to enhance oral delivery of peptides have been described in the literature. Generally, they include attachment of permeation enhancers (such as glycosides, lipids and PEG) and/or targeting proteolytic enzyme inhibitors. Exploration of multifunctional polymers as a polymeric matrix to provide controlled drug release and drug encapsulation in polymeric nanoparticulate systems has also been reported. Using ligand-specific binding and uptake techniques which employ vitamin B12, biotin, folate, and lectins to name a few, as drug carriers was also demonstrated. A more detailed discussion on these topics is covered elsewhere (Park et al. [@CR154]; Karsdal et al. [@CR102], [@CR103]). A brief discussion of lipidation phenomena affecting oral bioavailability with selected examples of biologically active peptides is described herein.

Chemical modification of the 32-amino acid salmon calcitonin (sCT) with an *N*-palmitoylated cysteine moiety attached to Cys-1 and Cys-7 of sCT *via* disulphide bonds greatly improved the bioavailability of the orally administrated native peptide (Wang et al. [@CR204]). Significant levels of sCT could still be detected in rat plasma up to 12 hours after oral administration of lipidated-sCT compared to undetectable levels after 1 hour when the same dose of native sCT was used (Wang et al. [@CR204]). In this report, a method termed 'reversible aqueous lipidization' (REAL) was used that allows for selective conjugation of a protein to a fatty acid *via* reversible disulphide linkage in aqueous solution using the water soluble *N*-palmitoyl cysteinyl 2-pyridyl disulphide reagent **15** (Scheme [9.1](#Sch1){ref-type="fig"}a) and the protein thiol (Ekrami et al. [@CR51]). The REAL technique was applied to the lipidation of other therapeutic peptide drugs including Bowman-Birk protease inhibitor (BBI) (Ekrami et al. [@CR51]), desmopressin (Wang et al. [@CR202]; Wang et al. [@CR203]) and octeotride (Yuan et al. [@CR227]).Scheme 9.1REAL technique to lipidate proteins *via* protein thiol (**a**) and *N*-terminal *N*α-amino group (**b**) (Ekrami et al. [@CR51]; Wang et al. [@CR205])

Peptide lipidation to improve oral bioavailability was also applied to the endogenous opioid peptide leu-enkephalin (ENK) using a modified REAL technique wherein 3,4-bis(decylthiomethyl)-2,5-furandione **16** was used to introduce a lipophilic moiety onto the *N*α-amino group of the *N*-terminus (Scheme [9.1](#Sch1){ref-type="fig"}b) (Wang et al. [@CR205]).

It has been reported that incorporation of lauric acid to the *N*-terminal pyroglutamyl group of thyrotropin-releasing hormone (TRH) significantly improved peptide penetration across the upper small intestine (Muranishi et al. [@CR149]; Tanaka et al. [@CR193]).

There is ongoing interest in developing an insulin formulation that could bypass the requirement for daily subcutaneous insulin injection for the management of diabetes (Wong et al. [@CR214]; Ramesan and Sharma [@CR163]). Promising reports on improved stability of mono- and di-palmitoylated insulin analogues in mucosal tissue homogenates compared to native insulin (Hashimoto et al. [@CR79]; Hashizume et al. [@CR80]) prompted further research into the effects of lipidation on the pharmacokinetic profile of insulin (Asada et al. [@CR6], [@CR7]). The effect of acylation on the stability and absorption of insulin from the small and large intestines was examined using mono- and di-acylated bovine insulin analogues (Asada et al. [@CR6], [@CR7]). Mono-acylated analogues were constructed *via* incorporation of caproic (C6), lauric (C12) and palmitic acid (C16) at the *N*α-amino group of Phe-1 of the insulin B chain; di-acylated analogues were prepared by modification of both the *N*α-amino group of Phe-1 and the *N*ε-amino group of Lys-29 of insulin B chain, with two copies of C6, C12, or C16 fatty acids (Fig. [9.10a](#Fig10){ref-type="fig"}). Mono-acylated analogues were found to be more stable in small intestinal fluid at 37 °C (Asada et al. [@CR6]) and increased absorption of caproic acid-modified analogues from the large intestine was observed compared to the native compound (Asada et al. [@CR7]).Fig. 9.10Lipidated insulin analogues created to improve oral bioavailability (Asada et al. [@CR7]; Clement et al. [@CR38], [@CR39]; Still [@CR190]; Kipnes et al. [@CR106])

Acylation of insulin and insulin analogues incorporating arginine residues at various sites within the insulin sequence, with various saturated and unsaturated fatty acids attached to the B chain showed improved solubility at moderately acidic pH inducing long-acting basal control of glucose levels (Flora [@CR56]).

Hexyl-insulin monoconjugate 2 (HIM2) is an insulin analogue that can be administrated as an oral semisolid formulation in hard gelatin capsules (Clement et al. [@CR38]; Still [@CR190]; Kipnes et al. [@CR106]; Clement et al. [@CR39]). HIM2 was created by chemical modification of recombinant insulin by covalent attachment of an amphiphilic oligomer consisting of a lipophilic alkyl unit (C6) and a hydrophilic PEG moiety covalently bound to the *N*ε amino group of the Lys-29 (B chain) (Fig. [9.10b](#Fig10){ref-type="fig"}) (Clement et al. [@CR38], [@CR39]; Still [@CR190]; Kipnes et al. [@CR106]).

Despite various scientific efforts, formulation of orally available insulin and other peptide-based drugs remains a challenging task (Lewis and Richard [@CR121]; Hamman et al. [@CR71]; Renukuntla et al. [@CR165]; Karsdal et al. [@CR102], [@CR103]).

Peptide lipidation has also been used to mimic the post-translational processes of sterol or lipid attachment facilitating protein association with cell membranes and subsequent initiation of protein activation or deactivation processes (Mejuch and Waldmann [@CR139]; Resh [@CR167]; Avadisian and Gunning [@CR8]). This nature-derived strategy is often designed to generate lipid-anchored drugs including lipidated peptide inhibitors with improved *in vivo* half-life and cell-penetrating potential. The lipid moiety attached to a peptide allows drug anchoring within the cell membrane and enabling action on soluble cytosolic proteins and membrane-bound/associated proteins (Avadisian and Gunning [@CR8]; Rajendran et al. [@CR162]). Cholesterol and fatty acids of various chain lengths such as C8-caprylic, C12-lauric, and C16-palmitic are often utilized as lipid motifs that are covalently attached to a peptide inhibitor *via* ester, ether, amide or carbamate bonds (Avadisian and Gunning [@CR8]; Zhao et al. [@CR237]; Wexler-Cohen and Shai [@CR208]; Remsberg et al. [@CR164]; Rajendran et al. [@CR160], [@CR161]; Porotto et al. [@CR158]; Johannessen et al. [@CR97]; Avadisian et al. [@CR9]).

This 'lipid anchoring technique' allowing for subcellular drug delivery by drug conjugation to a lipid *via* a linker, was recently used to effectively inhibit the action of endosomal β-secretase (Rajendran et al. [@CR160], [@CR161]). β-Secretase inhibitors may be useful for the treatment of Alzheimer's disease by blocking the enzyme involved in amyloid formation. The lipid-anchored inhibitors consist of three main parts which include the pharmacophore ('message'), the lipid anchor ('address'), and the linker which conjugates both parts together and allows for optimal flexibility of the pharmacophore within the lipid bilayer to bind with the target (Rajendran et al. [@CR162]). Simons et al. (Rajendran et al. [@CR160], [@CR161]) showed that that conjugation of a sterol to the β-secretase inhibitor (Glu-Val-Asn-statine-Val-Ala-Glu-Phe) *via* a polyglycol linker resulted in greater efficacy; β-secretase cleavage of β-amyloid precursor protein (APP) was decreased resulting in reduced β-amyloid peptide formation (Fig. [9.11](#Fig11){ref-type="fig"}). Importantly, the cholesterol-enriched drug was readily internalized into endosomes and cholesterol-sphingolipid domains (rafts) within cellular membranes where β-secretase activity is observed (Rajendran et al. [@CR160], [@CR161]; Hicks et al. [@CR82]; Cordy et al. [@CR41]). Comparison of stearyl-, palmityl-, myristyl-, and oleyl-linked inhibitors revealed cholesterol- and palmitoyl-linked analogues to be superior in terms of raft partitioning ability (Rajendran et al. [@CR160]).Fig. 9.11Sterol conjugation to the β-secretase inhibitor using lipid anchoring technique (Rajendran et al. [@CR162], [@CR160], [@CR161])

The lipidation site within the peptide chain is critical as it can determine the pharmacokinetic and pharmacodynamic properties of drug candidates by affecting the solubility and the self-aggregating potential of lipopeptides. Ward et al. (Ward et al. [@CR206]) investigated lipidated glucagon-based peptides to identify acylated co-agonists for the glucagon and glucagon-like peptide 1 receptors (GCGR and GLP-1R, respectively). A number of palmitoylated and *C*-amidated glucagon analogues were prepared where Ser-2 was substituted with an Aib moiety to prevent enzymatic degradation by dipeptidyl peptidase-4. The *N*ε-amino group of Lys-12 or an introduced lysine residue that was used to replace the mid-region moieties of glucagon, namely Tyr-10 or Tyr-13, Leu-14 or Ser-16, Arg-17 or Gln-20, was explored to attach a palmitic acid *via* a γGlu-γGlu dipeptide spacer (Ward et al. [@CR206]). The solubility and aggregate-forming potential of glucagon analogues in phosphate-buffered saline (PBS) (pH 7.4) was variable. Decreased solubility and increased aggregation was observed for the acylated analogue at position 14 which correlated with its reduced *in vivo* activity compared to the other analogues (Ward et al. [@CR206]). Interestingly, the study also revealed an increased proportion of helical content for all C16 fatty acid-tagged analogues in addition to improved potency at glucagon and GLP-1 receptors for most of the palmitoylated analogues. This is the first indication of enhancing *in vitro* receptor potency through helix stabilization by lipidation (Ward et al. [@CR206]). This finding further reinforced the importance of lipidation in the development of therapeutic peptides (Ward et al. [@CR206]). It was observed that saturated fatty acids with longer chains (\>C8) have greater conformation-stabilising potential compared with unsaturated or hydroxyl counterparts due to enhanced hydrophobic interactions with the peptide chains (Zhang and Bulaj [@CR233]). Lipidation was also shown to be an effective tool to induce peptide oligomerization and self-assembly resulting in the formation of micelles, tubules, vesicles, mono- and bilayer structures that can be used in both the drug delivery and tissue engineering fields (Zhang and Bulaj [@CR233]; Hutchinson et al. [@CR88]; Hamley [@CR70]).

Peptide lipidation is an effective strategy to increase the drugable potential of bioactive peptides and has been applied to many other biomolecules not mentioned in this report including angiotensin II (Maletínskâ et al. [@CR130]; Maletinska et al. [@CR131]), BBI (Honeycutt et al. [@CR86]), desmopressin (Wang et al. [@CR202]; Wang et al. [@CR203]), galanin, (Saar et al. [@CR176]; Robertson et al. [@CR172]; Zhang et al. [@CR234]), ghrelin (Bednarek et al. [@CR12]), neuropeptide Y (NPY) (Green et al. [@CR66]; Green et al. [@CR65]), octreotide (Yuan et al. [@CR227]), luteinizing hormone releasing hormone (LHRH) (Toth et al. [@CR197]), tetragastrin (Fujita et al. [@CR59]; Setoh et al. [@CR180]; Yodoya et al. [@CR225]), and more. Further details relating to the above mentioned lipidated analogues can be found in the recent review by Zhang and Bulaj (Zhang and Bulaj [@CR233]).

Pam~n~Cys Ligand as Adjuvant for Peptide-Based Vaccines {#Sec5}
-------------------------------------------------------

There has been significant interest directed towards the development and synthesis of peptide vaccines as alternatives to conventional vaccines, where potentially toxic, whole live attenuated or killed microorganisms are used to elicit immune responses (Simerska et al. [@CR183]; Moyle and Toth [@CR145]; Li et al. [@CR122]; Brown and Jackson [@CR20]). One of the limitations of peptide-based vaccines is the lack of immunogenicity thus requiring the inclusion of an effective and safe adjuvant (Simerska et al. [@CR183]; Moyle and Toth [@CR145]; Khong and Overwijk [@CR105]).

A less explored class of immune adjuvants are compounds stimulating innate-like T cells, semi-activated T cells with an invariant T cell receptor (TCR) represented by the invariant natural killer T cells (NKT) that recognize glycolipid antigens binding to the lipid antigen-presenting molecule CD1d (Fujii et al. [@CR58]; Hermans et al. [@CR81]). The most well-known CD1d ligand is α-galactosylceramide (α-GalCer, KRN 7000) (Godfrey and Kronenberg [@CR63]) and studies on the use of α-GalCer conjugated to peptide antigens generating potent self-adjuvanting vaccine constructs have been reported (Anderson et al. [@CR4], [@CR5] Cavallari et al. [@CR30]).

Toll-like receptors (TLRs) are transmembrane glycoproteins which play an important role in initiating an innate immunity response and developing the adaptive immune response (Gay and Gangloff [@CR61]; Basto and Leitao [@CR11]). Ten members of the human TLR family namely TLR1-TLR10 have been identified. TLR agonists vary and include viral genetic material, microbial nucleic acids and microbial membrane components (Mifsud et al. [@CR142]). Stimulation of TLRs may therefore lead to potent therapies against infectious diseases and many TLR ligands have been evaluated as potential treatments of viral and bacterial infections (Basto and Leitao [@CR11]; Mifsud et al. [@CR142]; Zaman and Toth [@CR228]; Khong and Overwijk [@CR105]).

Lipopeptides derived from bacterial cell wall components including lipoproteins, peptidoglycans, lipoteichoic acid and lipopolysaccharides can activate Toll-like receptor 2 (TLR2) (Basto and Leitao [@CR11]; Zaman and Toth [@CR228]). Conjugation of lipids and liposaccharides to peptide antigens is therefore used to elicit an immune response and plays an important role in self-adjuvanting vaccine development (Simerska et al. [@CR183]; Moyle and Toth [@CR145]; Zaman and Toth [@CR228]).

Common lipidated moieties employed in vaccine design to induce immunogenicity include synthetic analogues of lipoprotein components of *Escherichia coli* (Braun [@CR15]) and *Mycoplasma* (Muhlradt et al. [@CR147]; Muhlradt et al. [@CR146]), namely *S*-\[2,3-bis(palmitoyloxy)propyl\]-*N*-palmitoyl-[l]{.smallcaps}-cysteine (Pam~3~Cys) (**17**) and *S*-\[2,3-bis(palmitoyloxy)propyl\]-[l]{.smallcaps}-cysteine (Pam~2~Cys) (**18**) (Zeng et al. [@CR231]), respectively (Fig. [9.12](#Fig12){ref-type="fig"}) (Khong and Overwijk [@CR105]).Fig. 9.12Chemical structure of Pam~3~Cys (**17**), Pam~2~Cys (**18**), PamCys (**19**), *N*-acetylated PamCys (**20**) and UPam

Pam~3~Cys and Pam~2~Cys have been used as adjuvants in several peptide-based vaccine studies directed towards treating various infectious diseases including, HIV, HBV, hepatitis C (Chua et al. [@CR34]; Chua et al. [@CR35]; Eriksson and Jackson [@CR53]), Lyme disease and influenza (Moyle and Toth [@CR145]; Khong and Overwijk [@CR105]; Zaman and Toth [@CR228]; Chua et al. [@CR37]; Tan et al. [@CR192]) in addition to melanoma (Zom et al. [@CR238]). Better water solubility and similar or improved immunogenicity shown by Pam~2~Cys compared to Pam~3~Cys (Zaman and Toth [@CR228]; Jackson et al. [@CR94]), makes this motif an even more interesting synthetic target for incorporation into peptide-based vaccines. Structure-activity studies carried out for Pam~2~Cys demonstrated enhanced activity by the natural (*R*) configuration at the asymmetric glyceryl carbon, in comparison to the (*S*) isomer, namely *S*-\[2(*R*),3-bis(palmitoyloxy)propyl\]-[l]{.smallcaps}-cysteine \[(*R*)-Pam~2~Cys\], and *S*-\[2(*S*),3-bis(palmitoyloxy)propyl\]-[l]{.smallcaps}-cysteine \[(*S*)-Pam~2~Cys\], respectively (Moyle and Toth [@CR145]; Zaman and Toth [@CR228]; Wu et al. [@CR219]; Takeuchi et al. [@CR191]). Conversely, incorporation of the (*R*/*S*) diastereoisomer of Pam~3~Cys within the MUC1 antitumor vaccine construct elicited immune responses similar to that of the same MUC1 glycopeptide comprising only the (*R*)-enantiomer (Shi et al. [@CR181]).

It has been reported that the Pam~2~Cys fatty acid chain length plays a crucial role in determining TLR2 activation; the minimum carbon chain length required for immunogenic activity is C8 and the strength of immune response increases with carbon addition up to C16 (C18=C16\>C12\>C8) (Moyle and Toth [@CR145]; Zaman and Toth [@CR228]; Buwitt-Beckmann et al. [@CR24]; Chua et al. [@CR33]). A more soluble derivative of Pam~2~Cys, namely Pam~2~CysSK~4~ showed the most promising activity amongst a range of adjuvants tested in the evaluation of a *Chlamydia trachomatis* vaccine (Cheng et al. [@CR32]; Spohn et al. [@CR185]). It has been reported that the presence of a serine moiety within the Pam~2~CysSK~4~ motif plays a role in enhanced agonist activity for TLR2 (Wu et al. [@CR219]; Kang et al. [@CR101]).

Further SAR studies on Pam~2~CysSK~4~ led to identification of a structurally simpler and water soluble monopalmitoylted analogue **19** and its *N*α-amino acetylated variant **20** possessing strong TLR2-agonistic activities, comparable to that of Pam~2~CysSer, in human (but not murine) blood (Fig. [9.12](#Fig12){ref-type="fig"}) (Agnihotri et al. [@CR2]; Salunke et al. [@CR177]). The correct spacing between the ester-linked palmitate and the thioether was found to be crucial for activity of analogue **19** and replacement of the ethyl chain with a propyl chain resulted in loss of activity (Wu et al. [@CR219]; Agnihotri et al. [@CR2]; Salunke et al. [@CR177]).

Replacement of the native amide bond within the Pam~3~Cys motif with an urea led to discovery of a novel TLR2 ligand termed UPam; substitution of the native *N*-palmitoyl chain of Pam~3~Cys with an *N*-tetradecylcarbamyl moiety afforded a ligand with improved immunostimulatory activity compared to the parent lipopeptide (Fig. [9.12](#Fig12){ref-type="fig"}) (Zom et al. [@CR238], [@CR239]; Willems et al. [@CR213]).

The use of a cationic lipidated peptide such as R~4~Pam~2~Cys to elicit T-cell immunity *via* TLR2 stimulation was recently described; the strategy relies on electrostatic attraction of the R~4~Pam~2~Cys moiety with soluble protein antigens obviating the need for covalent bond generation between the TLR2 ligand and the antigen (Chua et al. [@CR36]).

The use of palmitic acid, lipoamino acids and other lipid-based immunopotentiators, as an alternative to Pam~n~Cys, covalently bound to synthetic (glyco)peptides to improve the self-adjuvanting effect of vaccine constructs has been reported and is reviewed elsewhere (Moyle and Toth [@CR145]; Khong and Overwijk [@CR105]; Basto and Leitao [@CR11]; Zaman and Toth [@CR228]; McDonald et al. [@CR136]; Steinhagen et al. [@CR187]).

Chemical Approaches for Incorporation of Pam~n~Cys Ligands {#Sec6}
----------------------------------------------------------

Finding efficient methods to conjugate antigens to lipopeptide adjuvants remains challenging (McDonald et al. [@CR136]). A simple and low-cost synthetic approach for peptide-lipid conjugation to effectively activate TLR2 to afford synthetic material in significant quantities for biological evaluation, is highly desired. A synthetic strategy must be devised using techniques from the chemistry toolbox that are compatible with the presence of lipid, carbohydrate and peptide moieties often required for self-adjuvanting vaccines. Herein, the most recent advances in synthetic techniques used to incorporate TLR2 ligands based on the Pam~n~Cys moiety into (glyco)peptides are summarized.

A solution phase synthesis of a simple dipeptide by direct condensation of *N*α-9-fluorenylmethoxycarbonyl (Fmoc)-protected *S*-(2,3-bis(hydroxyl)propyl)-[l]{.smallcaps}-cysteine with serine where the side chain hydroxyl is protected with a *tert-*butyl (*t*Bu) ether was reported by Jung et al. (Metzger et al. [@CR140]). Subsequent palmitoylation of *S*-glycerylcysteinyl hydroxyls using palmitic acid, *N*,*N*′-diisopropylcarbodiimide (DIC) and 4-(dimethylamino)pyridine (DMAP), followed by *t*Bu protecting group removal from the serine side chain effectively provided Fmoc-Pam~2~CysSer (Metzger et al. [@CR140]).

Danishefsky et al. (Kudryashov et al. [@CR113]) employed a solution phase approach to successfully incorporate the Pam~3~Cys ligand into a trivalent Lewis Y antigen resulting in antibody production in animal models. However, more common approaches to incorporate the Pam~n~Cys motif into peptides when designing a synthetic vaccine mostly rely on Fmoc solid phase peptide synthesis (SPPS). In this case, the peptide-based vaccine construct is synthesized first followed by lipid attachment. This approach however may prove problematic when synthesizing long or difficult peptide sequences (Zeng et al. [@CR232]).

Alternatively, a convergent or modular approach can be used requiring initial preparation of vaccine motifs that are later conjugated, mostly *via* a linker, affording a self-adjuvanting vaccine construct (Zeng et al. [@CR229], [@CR230], [@CR231], [@CR232]; Harris et al. [@CR77]; Buwitt-Beckmann et al. [@CR23]; Metzger et al. [@CR141]). The choice of chemical linkage used for adjuvant-antigen conjugation is very important and may influence the bioactivity of the construct (Zeng et al. [@CR232]).

### Convergent and Modular Approaches to Self-Adjuvanting Vaccine Constructs {#Sec7}

A fully synthetic convergent approach for the preparation of the minimal vaccine construct consisting of the *S*-\[2(*R*),3-bis(palmitoyloxy)propyl\]-*N*-palmitoyl-[l]{.smallcaps}-cysteine \[(*R*)-Pam~3~Cys)\], a helper T cell epitope and T~N~ antigen (GalNAc) leading to high titres of IgG antibodies in mice was reported by Boons et al. (Buskas et al. [@CR22]). In this example, the resin-bound and side chain protected peptide T cell epitope derived from an outer-membrane protein of *Neisseria meningitides* (Wiertz et al. [@CR209]) was first synthesized using Fmoc SPPS using the extremely acid sensitive 4-(4-hydroxymethyl-3-methoxyphenoxy)butyryl-*p*-methylbenzhydrylamine (HMPB-MBHA) resin affording H~2~N-Y(*t*Bu)AFK(Boc)Y(*t*Bu)AR(Pbf)H(Trt)AN(Trt)VGR(Pbf)N(Trt)AFE(O*t*Bu)LFLG-resin (**21**) (Scheme [9.2](#Sch2){ref-type="fig"}). To minimize racemization at cysteine, Pam~3~Cys was introduced into the epitope sequence using the Fmoc*-S*-\[2(*R*),3-bis(palmitoyloxy)propyl\]-[l]{.smallcaps}-cysteine (Fmoc-(*R*)-Pam~2~Cys-OH) **22** under the activation of (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP), 1-hydroxybenzotriazole (HOBt), *N*,*N*-iisopropylethylamine (*i*Pr~2~NEt) in a mixture of *N*,*N*-dimethylformamide (DMF) and CH~2~Cl~2~. Subsequent acylation of the Fmoc-deprotected *N*α-amino group of Cys with palmitic acid and using PyBOP and HOBt, followed by resin cleavage \[2% trifluoroacetic acid (TFA) in CH~2~Cl~2~\] gave the side-chain protected Pam~3~Cys-tagged lipidated peptide **23**. Finally, condensation of **23** with a spacer containing tumour-associated T~N~ antigen **24** activated by DIC, 1-hydroxy-7-azabenzotriazole (HOAt) and *i*Pr~2~NEt and ultimate side chain protecting group removal using 95% TFA gave the target vaccine construct **25** (Scheme [9.2](#Sch2){ref-type="fig"}) (Buskas et al. [@CR22])Scheme 9.2Convergent approach to a self-adjuvanting lipidated vaccine construct incorporating Pam~3~Cys TLR2 ligand by Boons et al. (Buskas et al. [@CR22]). Reagents and conditions: (*i*) **22**, PyBOP, HOBt, *i*Pr~2~NEt, DMF/CH~2~Cl~2~ (1:5, v/v); (*ii*) 20% piperidine in DMF; (*iii*) CH~3~(CH~2~)~14~COOH, PyBOP, HOBt, DMF/CH~2~Cl~2~ (1:5); (*iv*) 2% TFA in CH~2~Cl~2~; (*v*) **24**, DIC, HOAt, *i*Pr~2~NEt, DMF/CH~2~Cl~2~ (2:1, v/v), 79%; (*vi*) TFA/H~2~O/1,2-ethanedithiol (EDT) (95:2.5:2.5, v/v/v)

Jackson et al. (Zeng et al. [@CR232]) proposed a modular approach (Zeng et al. [@CR230]) for the preparation of self-adjuvanting vaccine constructs, where standard Fmoc SPPS was used. On-resin incorporation of the Fmoc-Pam~2~Cys-OH (Zeng et al. [@CR231]; Metzger et al. [@CR140]; Jones [@CR98]; Hida et al. [@CR83]) *via* a diserine spacer to the *N*ε of an *N*-terminal lysine afforded lipidated CD4^+^ T(T~H~) cell epitope (Zeng et al. [@CR229], [@CR231], [@CR232]). The lipid-tagged T~H~ epitopes were then further *N*-terminally modified to facilitate a chemoselective ligation with complementary functional groups present at the target epitope modules affording oxime-, thioether-, and disulphide bond-linked lipidated vaccine constructs, ready for antibody response studies using animal models (Zeng et al. [@CR232]).

Thus, Fmoc SPPS of T~H~ epitopes containing *N*-terminal lysine with *N*α-and *N*ε-amino groups orthogonally protected using 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde) and Fmoc protecting groups respectively, were prepared affording T~H~ constructs of general structure **26** (Scheme [9.3](#Sch3){ref-type="fig"}). Removal of the Fmoc protecting group using piperidine then allowed for peptide elongation *via* the exposed *N*ε-amino group to effect incorporation of the diserine spacer. Subsequently, the Fmoc-Pam~2~Cys-OH building block was attached using *N*-\[(1H-benzotriazol-1-yl)(dimethylamino)methylene\]-*N*-methylmethanaminium tetrafluoroborate *N*-oxide (TBTU), HOBt and *i*Pr~2~NEt in CH~2~Cl~2~. The Fmoc protecting group of Pam~2~Cys moiety was then exchanged for the *N*-(*tert*-butoxycarbonyl) (Boc) (di-*tert*-butyl dicarbonate, Boc~2~O) allowing for orthogonal removal of the Dde from the *N*-terminal amino group of Lys using 2% hydrazine hydrate in DMF, providing lipidated T~H~ construct **27**. Boc-Cys(Trt)-OH or (Boc-aminooxy)acetic acid were then coupled to the lipidated epitope **27** with subsequent peptide cleavage from the resin using TFA to give Pam~2~Cys-tagged T~H~ epitopes with sulphydryl- (**28**), or aminooxyacetyl-functionality (**29**) at the *N*-terminus, as handles for subsequent elongation with target epitopes (Scheme [9.3](#Sch3){ref-type="fig"}).Scheme 9.3Synthesis of lipidated-T~H~ epitopes incorporating Pam~2~Cys TLR2 ligand by Jackson et al. (Zeng et al. [@CR232]). Reagents and conditions: (*i*) 20% piperidine in DMF; (*ii*) Fmoc-Ser(*t*Bu)-OH, HBTU, HOBt, *i*Pr~2~Net, DMF, then (*i*), repeated twice; (*iii*) Fmoc-Pam~2~Cys-OH, TBTU, HOBt, *i*Pr~2~NEt, CH~2~Cl~2~, 16 h, then (*i*); (*iv*) Boc~2~O, DMF; (*v*) 2% hydrazine hydrate in DMF, 10 min; (*vi*) Boc-Cys(Trt)-OH, HBTU, HOBt, *i*Pr~2~Net, DMF; (*vii*) (Boc-aminooxy)acetic acid, DMF; (*viii*) TFA/phenol/H~2~O/triisopropylsilane (*i*Pr~3~SiH) (88:5:5:2)

The target epitopes were separately synthesized using Fmoc SPPS and their *N*-termini acylated with bromoacetic acid or cysteine while still bound to resin. TFA-mediated peptide cleavage from the resin subsequently afforded bromoacetyl-, and thiol-tagged epitopes **30** and **31**, respectively. Alternatively, an additional serine residue was inserted at the *N*-terminus of the peptide sequence allowing for off-resin and sodium periodate-mediated serine oxidation affording an epitope with an *N*-terminal aldehyde handle **32**. Chemoselective ligation between complementary-tagged T~H~ and target epitopes in buffer solutions, namely **28** and **30** (*aq* buffer, pH 8), **28** and **31** (2,2′-dipyridyl disulphide), **29** and **32** (*aq* buffer, pH 3) gave thioether-, disulphide, and oxime-bond linked self-adjuvanting peptide-based vaccine constructs **33**-**35**, ready for further bioanalysis (Zeng et al. [@CR232]) (Scheme [9.4](#Sch4){ref-type="fig"}).Scheme 9.4Schematic representation of modular approach to a self-adjuvanting lipidated vaccine constructs **33**-**35** incorporating Pam~2~Cys TLR2 ligand and different epitopes linked *via* thioether- (**33**), disulphide- (**34**), and oxime bond (**35**) by Jackson et al. (Zeng et al. [@CR232])

This modular approach (Zeng et al. [@CR230]) ensured that attachment of the Pam~2~Cys motif at the *N*ε-amino group of Lys "in between" both epitopes orientating the vaccine constructs in a branched configuration. The Pam~2~Cys motif can also be incorporated at the *N*α-amino group at the *N*-terminus of a vaccine construct; however, decreased immunogenic activity resulted following linear assembly, partially due to reduced solubility, compared to the branched vaccine counterparts (Zeng et al. [@CR231]).

A new thioether ligation strategy to create self-adjuvanting peptide vaccine constructs using the Pam~3~CysSK~4~ moiety has been recently reported (Cai et al. [@CR26]). This approach takes advantage of the complementary modified Pam~3~CysSK~4~ motif with a bromo-handle and thiol-containing antigen that are subsequently linked together *via* a thioether bond. Key to this approach was the initial preparation of an active intermediate Pam~3~CysSK~4~-K(COCH~2~Br)-OH **36** that was accessed by microwave-enhanced (MW) Fmoc SPPS. Herein, a Wang-resin was initially preloaded with lysine orthogonally protected with Fmoc at *N*α and with a 1-(4,4-dimethyl-2,6-dioxo-cyclohexylidene)-3-methyl-butyl (ivDde) at *N*ε. Subsequent peptide chain elongation *via* the *N*α-amino group followed by lipidation using Pam~3~Cys-pentafluorophenyl (Pfp) ester \[HOBt in *N*-methyl-2-pyrrolidone (NMP) for 45 min at 50 °C\] afforded resin-bound and side-chain protected Pam~3~CysS(O*t*Bu)\[K(Boc)\]~4~-K(ivDde). The ivDde protecting group was then removed using hydrazine, and the *N*ε-amino group acylated with pentafluorophenyl bromoacetate. Subsequent TFA-mediated peptide cleavage gave Pam~3~CysSK~4~-K(COCH~2~Br)-OH **36**. The key intermediate **36** was then converted into an active iodo-acetyl derivative using potassium iodide (KI) in urea/sodium acetate (NaOAc) mixture affording **37** (Scheme [9.5](#Sch5){ref-type="fig"}a). The iodo-acetyl moiety **37** was then ligated with several peptide epitopes that incorporated a thiol-terminated PEG spacer at their *N*-terminus. For example construct **38** was treated with **37** and trimethylamine (Et~3~N) in DMF at 40 °C affording construct **39** (Scheme [9.5](#Sch5){ref-type="fig"}b). The authors successfully applied this strategy for conjugation of a Pam~3~CysSK~4~ motif *via* a thioether linkage to B- and T-cell epitopes affording various self-adjuvanting vaccine constructs (Cai et al. [@CR26]). The three-component construct **39** comprising P4 tetanus toxoid T cell epitope (Demotz et al. [@CR47]; Monji and Pious [@CR144]), linked *via* a PEG spacer with MUC1 glycopeptide comprising T~N~ antigen, and a conjugated Pam~3~CysSK~4~ *via* a thioether linkage proved most efficacious (Cai et al. [@CR26]).Scheme 9.5Exemplified synthesis of three component synthetic vaccine incorporating Pam~3~Cys TLR2 ligand using thioether ligation strategy by Kunz et al. (Cai et al. [@CR26]). Reagents and conditions: (*i*) MW Fmoc SPPS; (*ii*) (*R*)-Pam~3~Cys-OPfp, HOBt, NMP, 45 min, 50 °C; (*iii*) 2% hydrazine hydrate in DMF, 5 min, rt (repeated 3 x); (*iv*) BrCH~2~COOPfp, HOBt, 4 h, rt; (*v*) TFA/*i*Pr~3~SiH/H~2~O (15:0.9:0.9, v/v/v); (*vi*) KI, 8 M urea/0.1M NaOAc, 30 min; (*vii*) NEt~3~, DMF, 40 °C

### Native Chemical Ligation Approach to Self-Adjuvanting Vaccine Constructs {#Sec8}

Native Chemical Ligation (NCL) (Dawson et al. [@CR44]) enables synthetic access to long peptides and large biomolecules and has been used by our research group in numerous studies (Yang et al. [@CR221]; Harris and Brimble [@CR76]; Medini et al. [@CR137]; Harris et al. [@CR78]; Harris and Brimble [@CR75]; Medini et al. [@CR138]; Lee et al. [@CR119]; Brimble et al. [@CR18]; Son et al. [@CR184]; Harris and Brimble [@CR74]). NCL conjugates two synthetic partners containing complementary reactive sites, namely an *N*-terminal cysteine and a *C*-terminal thioester moiety *via* a thiol-catalysed chemoselective reaction affording a thioester-linked product; subsequent S→N transfer ensures the formation of a native peptide bond (Dawson et al. [@CR44]). Brimble et al. (Harris et al. [@CR77]) explored synthetic pathways to access Pam~2~Cys-linked thioester moiety that could be later incorporated into a long peptide *via* NCL. The initial effort to synthesise a more soluble derivative of Pam~2~Cys, namely Pam~2~CysSK~4~G thioester using *tert-*butyloxycarbonyl (Boc) SPPS resulted in unexpected cleavage of the palmitoyl esters during the final hydrofluoric acid (HF)-mediated peptide removal from the resin (Zeng et al. [@CR232]). Successful synthesis of Pam~2~CysSK~4~G thioester was however completed using an alternative Fmoc SPPS strategy employing a sulfonamide 'safety catch linker' (Backes and Ellman [@CR10]; Ingenito et al. [@CR93]) and Fmoc*-S*-\[2(*S*),3-bis(palmitoyloxy)propyl\]-[l]{.smallcaps}-cysteine (Fmoc-(*S*)-Pam~2~Cys-OH) (**40**) as the building block (Scheme [9.6](#Sch6){ref-type="fig"}) (Harris et al. [@CR77]). Loading of 4-sulfamylbutyryl aminomethyl polystyrene resin with Fmoc-Gly-OH was initially performed \[DIC, *N*-methylimidazole (*N*-Melm) in DMF/CH~2~Cl~2~ mixture\] followed by standard Fmoc SPPS affording side chain protected peptidyl-resin **41**. Subsequent coupling of lipidated building block **40** (Metzger et al. [@CR140]; Hida et al. [@CR83]) was effected (PyBOP/HOBt) and the Fmoc protecting group was exchanged to Boc (Boc~2~O in DMF/CH~2~Cl~2~ mixture) to provide **42**. Resin-bound **42** was then activated with iodoacetonitrile in NMP, with subsequent cleavage from resin using benzyl thiol (BnSH). Finally side chain protecting groups removal using TFA afforded the desired Pam~2~CysSK~4~G thioester **43** (Harris et al. [@CR77]).Scheme 9.6Synthesis of a *C*-terminal thioester derivative of the Pam~2~CysSKKKK using Fmoc SPPS by Brimble et al. (Harris et al. [@CR77]). Reagents and conditions: (*i*) Fmoc-Gly-OH, DIC, *N*-Melm, CH~2~Cl~2~, DMF; (*ii*) Fmoc SPPS; (*iii*) **40**, PyBOP, HOBt, CH~2~Cl~2~; (*iv*) 20% piperidine in DMF; (*v*) Boc~2~O, CH~2~Cl~2~, DMF; (*vi*) ICH~2~CN, NMP; (*vii*) BnSH, DMF; (*viii*) TFA/phenol/*i*Pr~3~SiH/H~2~O (88:5:2:5, v/v/v/v)

Boons et al. (Ingale et al. [@CR90]) were the first to demonstrate a successful synthesis of a three-component glycolipidated peptide vaccine by sequential NCL of the suitably prepared ligation fragments; Fmoc SPPS was employed to synthesise the T-cell epitope C(Acm)YAFKYARHANVGRNAFELFLG-thioester (**44**), the tumour-associated glycopeptide fragment derived from MUC-1 CTSAPDT(GalNAc)RPAP (**45**), and the TLR2 ligand Pam~3~CysSK~4~G-thioester (**46**). Due to limited success when ligation of **44** with **45** was undertaken using standard NCL conditions (phosphate buffer containing 6 M guanidinium hydrochloride, thiophenol, 37 °C), new methodology involving incorporation of **44** with **45** into liposomes to aid solubility was used. A film of dodecylphosphocholine (DPC), thioester **44** and thiol **45** were hydrated *via* incubating in a phosphate buffer (pH 7.5) for 4 h at 37 °C in the presence of tris(2-carboxyethyl)phosphine (TCEP) and ethylenediaminetetraacetic acid (EDTA) to suppress disulphide bond formation. The mixture was then sonicated and the resulting peptide/lipid suspension formed uniform 1 μm vesicles. Sodium 2-mercaptoethane sulfonate (MESNA) was subsequently added and ligation completed after 2 h at 37 °C affording **47** in high 78% yield after reversed-phase high-performance column chromatography (RP HPLC) purification (Ingale et al. [@CR90]). Ligation of Pam~3~CysSK~4~G-thioester **46** with thiol **48**, accessed by removal of the acetamidomethyl (Acm) protecting group from **47** \[Hg(OAc)~2~\], using liposome-mediated NCL afforded a three-component vaccine construct **49** in 83% yield after purification by chromatography (Scheme [9.7](#Sch7){ref-type="fig"}). The scope of this technique was later demonstrated by the synthesis of other self-adjuvanting vaccine constructs that differ in the composition of the (glyco)peptide and lipid component; some of the constructs proved highly immunogenic when tested in mice models (Ingale et al. [@CR90]; Ingale et al. [@CR91]; Lakshminarayanan et al. [@CR115]; Abdel-Aal et al. [@CR1]; Ingale et al. [@CR92]).Scheme 9.7Liposome-mediated NCL to the synthesis of three-component vaccine construct incorporating Pam~3~Cys TLR2 ligand by Boons et al. (Ingale et al. [@CR90]). Reagents and conditions: (*i*) 200 mM sodium phosphate buffer (pH 7.5), DPC, TCEP, EDTA, sonication, extrusion, and then MESNA; (*ii*) Hg(OAc)~2~, 10% *aq* HOAc, 50 mM [dl]{.smallcaps}-dithiothreitol (DTT), 89%

The liposome-mediated NCL approach allowed for the generation of a native amide linkage between each of the required vaccine modules. However, the use of dodecylphosphocholine liposomes in ligation buffers can be limiting owing to the need for RP HPLC purification after each ligation step to isolate the product (McDonald et al. [@CR136]; Ingale et al. [@CR90]).

### Fragment Condensation Approach to Self-Adjuvanting Vaccine Constructs {#Sec9}

Kunz et al. (Kaiser et al. [@CR99]) and Payne et al. (Wilkinson et al. [@CR210]) described a fragment condensation approach to incorporate a Pam~3~Cys TLR2 ligand into mono- and per-glycosylated MUC1 glycopeptides respectively, using a PEG-based spacer to access fully synthetic vaccine constructs.

The Kunz approach involved initial synthesis of the lipidated, side-chain protected and the *C*-terminal carboxylic acid Pam~3~CysS(*t*Bu)K(Boc)K(Boc)K(Boc)K(Boc) (**50**) unit using Fmoc SPPS. The MUC1 glycopeptides *N*-terminally modified with PEG linker, namely H~2~N(CH~2~CH~2~O)~3~CH~2~CH~2~CONH-PAH-GVT(sugar)-SAP-DTR-PAP-GST-AP-OH, comprising either T~N~- (**51**), T- (**52**) or 2,6-sialyl-T-antigen (**53**) at the singly glycosylated Thr-6 were then accessed *via* Fmoc SPPS. The fragment condensation was subsequently effected in solution and using *N*-\[(dimethylamino)-1*H*-1,2,3-triazolo\[4,5-*b*\]pyridin-1-ylmethylene\]-*N*-methylmethanaminium hexafluorophosphate *N*-oxide (HATU)/HOAt and 4-methylmorpholine (NMM) in DMF which was followed by TFA-mediated protecting group removal and purification affording three novel vaccine constructs, **54**, **55** and **56** in 25%, 21% and 20% yield, respectively (Scheme [9.8](#Sch8){ref-type="fig"}). Importantly, bio-assessment of TLR2 ligand-MUC1 assembly comprising T-antigen **55** showed the ability to elicit humoral immune response in mice (Kaiser et al. [@CR99]).Scheme 9.8Fragment condensation for the synthesis of the vaccine construct incorporating Pam~3~Cys TLR2 ligand by Kunz et al. (Kaiser et al. [@CR99]). Reagents and conditions: (*i*) HATU, HOAt, NMM, DMF; (*ii*) TFA/*i*Pr~3~SiH/H~2~O (10:1:1, v/v/v), 1.5 h

The Payne group employed the lipopeptide component with a PEG-like spacer at *C*-terminus, namely Pam~3~CysS(*t*Bu)-CONH(CH~2~CH~2~O)~2~CH~2~COOH (**57**), and per-glycosylated full copies of the MUC1 VNTR domain epitope (GVT(sugar)-S(sugar)-APDT(sugar)-RPAPGS(sugar)T(sugar)APPAH), incorporating no copies (**58**) or multiple-copies of either T~N~- (**59**) or T-antigen (**60**), for convergent conjugation. All peptide fragments **57**-**60** were synthesized using Fmoc SPPS. The free carboxylic acid of the lipid partner **57** was pre-activated using pentafluorophenyl ester with ensuing fragment condensation with the requisite MUC1 epitopes **58**, **59** or **60** using HOBt and *i*Pr~2~NEt in DMF affording desired MUC1-Pam~3~Cys chimeras with no sugars **60**, or containing five copies of either T~N~-or T-antigen, **62** and **63**, respectively (Scheme [9.9](#Sch9){ref-type="fig"}) (Wilkinson et al. [@CR210]). This fragment condensation approach was also used in other studies by the Payne group to synthesise multiple-component vaccine constructs incorporating Pam~3~Cys (Wilkinson et al. [@CR212]; McDonald et al. [@CR135]; Wilkinson et al. [@CR211]). The fragment condensation strategy is a good alternative to the liposome-mediated NCL approach reported by Boons et al. (Ingale et al. [@CR90], [@CR91]; Lakshminarayanan et al. [@CR115]) with no requirements for solubilizing agents.Scheme 9.9Fragment condensation approach for the synthesis of vaccine constructs incorporating Pam~3~Cys by Payne et al. (Wilkinson et al. [@CR210]). Reagents and conditions: (*i*) pentafluorophenol, DIC, CH~2~Cl~2~;(*ii*) **58** or **59** or **60**, HOBt, *i*Pr~2~NEt, DMF; (*iii*) TFA/*i*Pr~3~SiH (1:1, v/v)

### Linear Approach to Self-Adjuvanting Vaccine Construct {#Sec10}

The Boons group has recently reported a linear synthesis to access a three-component cancer vaccine composed of a B-cell epitope glycosylated with a sialyl-T~N~ moiety, a T~H~ epitope derived from polio virus (Leclerc et al. [@CR118]) and a Pam~3~CysSK~4~ ligand. The key strategies employed by the Boons group included the use of microwave-enahanced Fmoc SPPS and on resin incorporation of the Fmoc-(*S*)-Pam~2~Cys-OH (**40**) building block onto the free *N*α-amino group of the pre-synthesised glycopeptide construct containing deprotected hydroxyl groups of the sugar moiety (Thompson et al. [@CR194]). Fmoc protecting group removal from the Fmoc-(*S*)-Pam~2~Cys-tagged vaccine construct (piperidine) could be then followed by *N*α-amino group palmitoylation using palmitic acid, HATU, HOAt and *i*Pr~2~NEt in DMF. Finally, TFA treatment afforded fully synthetic vaccine construct **64** incorporating the Pam~3~Cys TLR2 ligand (Fig. [9.13](#Fig13){ref-type="fig"}). Biological evaluation demonstrated induction of potent humoral and cellular immune responses in transgenic mice (Thompson et al. [@CR194]).Fig. 9.13A fully synthetic vaccine construct prepared using MW-enhanced linear Fmoc SPPS and incorporating Pam~3~Cys TLR2 ligand by Boons et al. (Thompson et al. [@CR194])

A three-component vaccine construct similar to that described above, but incorporating the unnatural T~N~ moiety, namely α-*O*-GalNAc-α-methylserine in place of threonine, within the MUC1 epitope was recently accessed using the MW-enhanced Fmoc SPPS strategy previously reported by Boons et al. (Thompson et al. [@CR194]; Martinez-Saez et al. [@CR133]). This novel vaccine construct however, showed only comparable efficacy to that reported for the assembly containing native threonine.

As shown above, a linear approach for the synthesis of complex multi-component lipidated peptides containing only natural peptide bonds demonstrates the efficiency of the microwave-assisted Fmoc SPPS technique. However, longer and/or more hydrophobic lipopeptide constructs may still be difficult to access when using a linear SPPS and alternative synthetic routes for lipid incorporation are in demand.

### TLR2 Ligand Conjugation Using Copper(I)-Catalysed Huisgen 1,3-Dipolar Cycloaddition {#Sec11}

The need for large quantities of Fmoc-Pam~2~Cys building block required for SPPS conjugation poses a considerable obstacle due to the difficulty and cost involved in its synthesis. An alternative conjugation approach to incorporate the Pam~2~Cys moiety into a peptide could mitigate this conundrum. The copper(I)-catalysed Huisgen 1,3-dipolar cycloaddition of alkynes and azides to afford a 1,2,3-triazole conjugate (CuAAC 'click chemistry') offered promise for the conjugation of Pam~2~Cys with a peptide due to its tolerance of various functional groups and its complete regioselectivity to form 1,4-disubstituted products (Tornoe et al. [@CR196]; Rostovtsev et al. [@CR174]). The Brimble group therefore designed a Pam~2~Cys click building block containing an azide handle in place of the *N*α-amino group of the cysteine residue which could be then clicked to a peptide functionalized with a propargyl moiety (Yeung et al. [@CR224]). However, initial attempts to directly introduce an azide onto a free *N*α-amino group of Pam~2~Cys using a diazotransfer reaction (Goddard-Borger and Stick [@CR62]) proved unsuccessful, potentially due to obstruction of the reactive sites by the long palmitate groups (Yeung et al. [@CR224]). A revised strategy was developed starting from an *S*-glyceryl cysteine intermediate **65** (Metzger et al. [@CR140]; Pattabiraman et al. [@CR155]) which was subjected to *N*α-amino group deprotection (piperidine in CH~2~Cl~2~) to reveal the amino group for the ensuing diazotranfer reaction using imidazole-1-sulfonylazide^.^HCl, K~2~CO~3~ and CuSO~4~ ^.^5H~2~O in MeOH (Goddard-Borger and Stick [@CR62]) affording an azide-diol in 50% yield over 2 steps (Scheme [9.10](#Sch10){ref-type="fig"}a). Subsequent palmitoylation of the azide-diol \[palmitic acid, DIC, and catalytic 4-(dimethylamino)pyridine (DMAP)\] provided *t*Bu-protected Pam~2~Cys azide **66** in 74% yield. Subsequent TFA treatment to remove the carboxyl protecting group gave the desired lipidated and azide-tagged 'click' ligation partner **67** in 84% yield (Yeung et al. [@CR224]).Scheme 9.10Synthesis of Pam~2~Cys azide **67** and Cu(I) 'click' conjugation of **67** with alkyne-modified peptides to get lipidated **70** and **71** by Brimble et al. (Yeung et al. [@CR224]). Reagents and conditions: (*i*) piperidine, CH~2~Cl~2~, then imidazole-1-sulfonyl azide·HCl, K~2~CO~3~, CuSO~4~, MeOH, 50% over 2 steps;(*ii*) CH~3~(CH~2~)~14~COOH, DIC, DMAP, tetrahydrofuran (THF), 74%;(*iii*) TFA, 84%; (*iv*) CuI·P(OEt)~3~, *i*Pr~2~NEt, DMF, 30 min

The synthesis of the alkyne-containing peptides for subsequent Cu(I) conjugation with **67** was undertaken using Fmoc SPPS (Yeung et al. [@CR224]). Pentynoyl acid was coupled to the *N*-terminus affording **68** and propargylglycine (Pra) was used as an alkyne handle within the modified MUC1 peptide sequence, namely HGV-Pra-SAPDTRPAPGSTAPPA **69**. The 'click' reaction of both alkyne-enriched peptides **68** and **69** using azide **67** was completed within 30 min as evidenced by RP HPLC using CuI·P(OEt)~3~ and *i*Pr~2~NEt in DMF affording 1,2,3-triazole-linked Pam~2~Cys peptides **70** and **71**, respectively. The amenability of the Pam~2~Cys azide to direct conjugation onto suitably modified peptides using the 'click' technique was successfully demonstrated (Scheme [9.10](#Sch10){ref-type="fig"}b) (Yeung et al. [@CR224]). However, construct **70** was immunologically inactive possibly due to difference in the distance between the serine and the Pam~2~Cys (unpublished data). It has been reported that the exact length and geometry around the Cys-Ser unit is critical for activity of the Pam~2~CysSK~4~ motif (Wu et al. [@CR219]; Kang et al. [@CR101]).

Kunz et al. were the first to report CuAAC-assisted ligation of Pam~3~CysSK~4~ to a MUC1 glycopeptide to synthesise mono-, di- and tetra-valent MUC1 tandem repeat glycopeptide constructs to prepare of fully synthetic antitumour vaccines (Cai et al. [@CR25]). The Kunz approach for the synthesis of monovalent MUC1 derivatives used Fmoc SPPS of MUC1 glycopeptide in which the *N*-terminal *N*α-amino group was acylated with a PEG linker suitably modified with an azide handle affording construct **72**. The 'click' synthetic partner **73** incorporated an alkyne group *via* a PEG spacer linking with the Pam~3~CysSK~4~ ligand by the *N*ε-amino group of the additional *C*-terminal lysine residue. The copper(I)-mediated reaction of the suitably prepared 'click' partners was then performed using copper acetate and Na ascorbate in H~2~O at 40 °C affording the monovalent vaccine construct **74** with \>70% yield (Scheme [9.11](#Sch11){ref-type="fig"}) (Cai et al. [@CR25]).Scheme 9.11Synthesis of mono-valent 'click' construct **74** from azide-modified MUC1 antigen **72** and alkyne-modified Pam~3~Cys **73** and graphical representation of di- and tetra-valent vaccine constructs **75** and **76** by Kuntz et al. (Cai et al. [@CR25], [@CR27]). Reagents and conditions: (*i*) copper acetate, Na ascorbate, H~2~O, 40 °C, \>70%

The *N*ε-amino group of the *C*-terminal lysine linked to the Pam~3~CysSK~4~ moiety was later used as a point of attachment of additional lysine groups forming a multibranched lysine core which terminated with two or four copies of PEG-alkyne handles. Subsequent Cu(I) 'click' using the Pam~3~CysSK~4~ ligand incorporating two- or four alkyne groups and azide construct **72** afforded the desired di- (**75**) and tetra-valent (**76**) assemblies, respectively (Scheme [9.11](#Sch11){ref-type="fig"}) (Cai et al. [@CR25]). Importantly, the tetravalent construct of general structure **76** synthesized using this strategy that incorporated the ST~N~ glycoside within the MUC1 sequence proved effective in inducing strong immune responses in mice including stimulation of killer cells (Cai et al. [@CR27]).

The Sucheck group has reported the 1,2,3-triazole-mediated conjugation of a Pam~3~Cys ligand equipped with a *C*-terminal alkyne, with a 20-amino acid azide-tagged tandem repeat of MUC1 incorporating the T~N~ unit (Sarkar et al. [@CR178]). The alkyne-containing 'click' partner was available from Fmoc-Pam~2~Cys(O*t*Bu) **77** by *tert*-butyl protection removal (TFA) followed by coupling with propargyl amine in the presence of PyBOP, HOBt and *i*Pr~2~NEt in CH~2~Cl~2~. Fmoc protecting group removal and acylation of the revealed *N*α-amino group with palmitic acid using PyBOP, HOBt, and *i*Pr~2~NEt gave the alkyne functionalized Pam~3~Cys **78**, Scheme [9.12](#Sch12){ref-type="fig"}a. The glycopeptide-azide was prepared *via* Fmoc SPPS on Fmoc-Ala-WANG resin using DIC/HOBt as coupling reagent and piperidine in DMF for Fmoc removal, affording resin-bound **79**. The azido group was installed on-resin by coupling 6-azidohexanoic acid to the *N*-terminal proline residue of MUC1 followed by TFA-mediated peptide cleavage from the resin and acetyl deprotection of the T~N~ hydroxyls (sodium methoxide in MeOH) to provide azide-containing MUC1 epitope **80** (Scheme [9.12](#Sch12){ref-type="fig"}b). The 'click' conjugation of both constructs, alkyne-functionalized Pam~3~Cys **78** and the azide-MUC1 component **80** was undertaken with CuSO~4~ ^.^5H~2~O, Na ascorbate with the aid of a Cu(I) stabilizing agent tris\[(1-benzyl-1*H*-1,2,3-triazol-4-yn)methyl\]amine (TBTA) in water/MeOH/THF mixture affording Pam~3~Cys-MUC1 conjugate **81** quantitatively (Scheme [9.12](#Sch12){ref-type="fig"}c) (Sarkar et al. [@CR178]).Scheme 9.12Synthesis of Pam~3~Cys-MUC1-T~N~ conjugate using 'click' chemistry by Sucheck et al. (Sarkar et al. [@CR178]). Reagents and conditions: (*i*) TFA, 1 h, rt, then propargyl amine, PyBOP, HOBt, *i*Pr~2~NEt, 4 Å molecular sieves, CH~2~Cl~2~, 4 h, rt, 66% over two steps; (*ii*) CH~3~CN/CH~2~Cl~2~/Et~2~NH (2:1:2), 2 h, rt, then CH~3~(CH~2~)~14~COOH, PyBOP, HOBt, *i*Pr~2~NEt, 4 Å molecular sieves, CH~2~Cl~2~, 4 h, rt, 80% over two steps; (*iii*) 6-azidohexanoic acid, DIC, HOBt, NMP; (*iv*) TFA/thioanisole/EDT/H~2~O phenol (88:3:5:2:2, v/v/v/v/v); (*v*) NaOMe, MeOH, 2 h, rt, 100%; (*vi*) CuSO~4~·5H~2~O, Na ascorbate, TBTA, H~2~O/MeOH/THF (1:1:2), 40 h, rt, 100%

The Brimble group recently employed a Pam~2~CysSK~4~ motif for the synthesis of a series of lipopeptide-based TLR2 agonists using 'click' chemistry (Wright et al. [@CR218]). Incorporation of an acetylene handle at the *C*-terminal end of the Pam~2~CysSK~4~ construct would allowing for the chemoselective 'click' conjugation with an azide-tagged epitope. Unlike the previous study by the Brimble group (Yeung et al. [@CR224]) this approach maintained the critical atomic distance between the Pam~2~Cys and adjacent serine moiety\[159\]. Additionally, both the self-adjuvanting lipopeptide construct and the epitope were directly conjugated *via* a 1,2,3-triazole unit in contrast to approach by Kunz et al. where a PEG linker spaced these units apart (Cai et al. [@CR25]).

It has been reported that the immunogenicity of the antigen incorporated to a vaccine construct may be suppressed by the presence of a linker (Buskas et al. [@CR21]). We were also interested if the location of the triazole between the antigen and the Pam~2~CysSK~4~ moiety affects the TLR2-mediated stimulation of innate immunity; antigen conjugation with the lipid at either the *N*- or *C*-terminus of the peptide antigen was therefore investigated. It has been reported that acetylation of the *N*α-amino group of the monoacyl PamCys moiety improved TLR2 activity (Salunke et al. [@CR177]) hence the effects of this modification were also evaluated in this study (Wright et al. [@CR218]).

A lipidated and *C*-propargylated 'click' partner **82**, in addition to the *N*-acetylated analogue **83** were first synthesized (Scheme [9.13](#Sch13){ref-type="fig"}a). Synthesis began by the *N*-terminal coupling of the Fmoc-(*S*)-Pam~2~Cys-OH building block **40** prepared from [l]{.smallcaps}-cysteine (Zeng et al. [@CR231]; Metzger et al. [@CR140]; Jones [@CR98]; Hida et al. [@CR83]), to the resin-bound *C*-terminal propargylated H~2~N-S(tBu)K(Boc)K(Boc)K(Boc)K(Boc)-Pra-resin peptide synthesized using standard Fmoc SPPS (Wright et al. [@CR218]). The peptide was lipidated using **40** and conditions adapted from Albericio et al. \[benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP), 2,4,6-collidine, CH~2~Cl~2~/DCM (1:1)\] (Han et al. [@CR72]). Subsequent Fmoc-deprotection, followed by TFA-mediated resin cleavage and RP HPLC purification afforded the desired construct **82**. Acylation of the *N*α-amino group of cysteine to give **83** was performed using a mixture of acetic anhydride and *i*Pr~2~NEt in DMF, prior to peptide cleavage and purification (Wright et al. [@CR218]). A truncated fragment of ppUL83 protein, namely NLVPMVATV, derived from the cytomegalovirus (CMV) known to stimulate CD8^+^ cytotoxic T-cells (Kopycinski et al. [@CR111]) was chosen as a model epitope for the 'click' reaction. Synthesis of two NLVPMVATV analogues incorporating an azide handle at either the *N*- or *C*-terminus was also required. For the preparation of an azide-tagged antigen at the *N*-terminal site of the peptide **84**, Fmoc SPPS was employed starting from 4-(hydroxymethyl)phenoxypropanoic acid (HMPP) resin and coupling of 2-azidoacetic acid to the *N*-terminal Asn at the last step of the SPPS. Subsequent acid-mediated peptide cleavage from the resin followed by RP HPLC purification afforded the desired 'click' partner **84** (Scheme [9.13](#Sch13){ref-type="fig"}b).Scheme 9.13Synthesis of Pam~2~Cys lipopeptide-based TLR2 agonists using 'click' chemistry by Brimble et al. (Wright et al. [@CR218]). Reagents and conditions: (*i*) **40**, BOP, 2,4,6-collidine, CH~2~Cl~2~/DMF (1:1); (*ii*) 20% piperidine in DMF; (*iii*) Ac~2~O, *i*Pr~2~NEt, DMF (only for **83**); (*iv*) TFA/*i*Pr~3~SiH/DODT/H~2~O (94:1:2.5:2.5, v/v/v/v), 4 h, rt; (*v*) CuSO~4~, Na ascorbate, DMSO, 10 min, 70 °C

For the synthesis of the NLVPMVATV analogue with the *C*-terminally-tagged azide moiety 2-azidoacetic acid was incorporated *via* the *N*ε-amino group of an inserted lysine moiety at the *C*-terminus of the peptide. An orthogonally protected lysine residue \[Dde-Lys(Fmoc)\] was coupled to the Rink-amide resin, followed by the selective *N*ε-Fmoc protecting group removal (20% piperidine in DMF) and coupling of the 2-azidoacetic acid moiety. Subsequent hydrazine hydrate-mediated Dde group deprotection allowed for the iterative peptide chain elongation using Fmoc SPPS through readily unmasked *N*α-amino group of the lysine residue, affording construct **85** (Scheme [9.13](#Sch13){ref-type="fig"}b). Chemoselective conjugation of propargylated-, or propargylated and *N*-acetylated- Pam~2~CysSK~4~ motives **82** and **83**, respectively with azidopeptides **84** and **85** under activation with CuSO~4~ and Na ascorbate in DMSO, gave 1,2,3-triazole-linked constructs **86**-**89** in good yields (30-40%) and high purities (\>95% by RP HPLC) (Scheme [9.13](#Sch13){ref-type="fig"}c) (Wright et al. [@CR218]).

Biological evaluation of **82** and *N*-acetylated analogue **83** using fresh human blood and measuring the level of CD80 surface expression compared to commercially sourced Pam~3~CSK~4~ interestingly revealed no major difference in CD80 expression between both propargylated Pam~2~Cys analogues with free- (**82**) and *N*-acetylated-*N*α-amine (**83**) in contrast to published reports (Salunke et al. [@CR177]). Importantly, there were no preferences regarding the *N*- or *C*-terminus for the antigen conjugation with lipidated adjuvant *via* 1,2,3-triazole and similar CD80 expression levels were observed for both 'clicked' analogues **86** and **87** and activity of 'clicked' lipopetides was comparable with the activity of commercially available Pam~3~CysSK~4~ (Wright et al. [@CR218]). This efficient procedure can therefore be generally applied for rapid generation of lipopeptides providing access to vaccine constructs (Wright et al. [@CR218]).

### Cysteine Lipidation on a Peptide or Amino acid (CLipPA) {#Sec12}

The ' thiol-ene' reaction, a radical-promoted alkylation of a thiol with an alkene has been gaining in popularity in polymer and material science (Lowe [@CR125]; Lowe [@CR126]) as well as providing an effective strategy for bioconjugation and for site-selective modification of protein and organic molecules (Dondoni and Marra [@CR50]; Hoyle and Bowman [@CR87]; Liu and Li [@CR124]; Krall et al. [@CR112]; Madder and Gunnoo [@CR127]). The Brimble group have recently applied for the first time, a single step ' thiol-ene' coupling to synthesise monoacyl lipopeptides that showed self-adjuvanting antigenic activity with potency comparable to that of the synthetically challenging Pam~3~Cys moiety (Wright et al. [@CR216], [@CR217]; Brimble et al. [@CR17]). We envisaged lipid attachment *via* the 'post-translational' route where the desired peptide constructs incorporating a cysteine at the *N*-terminus are first synthesized followed by *S*-lipidation with inexpensive and commercially available vinyl palmitate using the ' thiol-ene' reaction. The viability of the transformation was first tested by preparation of the *S*-palmitoylated, *N*α-Fmoc protected cysteine, starting from commercially available Fmoc-Cys(Trt)-OH which thiol protecting group was removed (TFA) affording Fmoc-Cys-OH (**90**). This was followed by hydrothiolation of vinyl palmitate **91** using UV light at 365 nm and 2,2-dimethoxy-2-phenylacetophenone (DMPA) as photoinitiator in CH~2~Cl~2~ for 60 min. The *S*-palmitoylated, *N*α-Fmoc protected cysteine **92** was obtained in satisfactory yield (44%) (Scheme [9.14](#Sch14){ref-type="fig"}a) (Wright et al. [@CR216], [@CR217]). Subsequent direct lipidation of short, unprotected peptides CysSK~4~ and *N*α-acetylated CysSK~4~ using **91**, DMPA and photoinitiation (365 nm), was examined. The study revealed the need for extraneous thiols to obviate problems of vinyl palmitate telomerization and mixed disulphide formation. The choice of solvent also proved critical for a successful reaction. The optimized ' thiol-ene' conditions (DMPA, DTT as thiol additive, NMP, h*ν* 365 nm) were then used to directly lipidate *N*α-acetylated CysSK~4~ **93** using vinyl palmitate (**91**) with high conversion (\>90%) to the *S*-palmitoylated peptide **94** (Scheme [9.14](#Sch14){ref-type="fig"}b).Scheme 9.14(**a**) Model ' thiol-ene' reaction of Fmoc-Cys-OH (**90**) with vinyl palmitate (**91**). (b) Direct *S*- palmitoylation of **93** and antigenic peptide **95** using vinyl palmitate **91** and 'thiol-ene' reaction by Brimble et al. (Wright et al. [@CR216]; Wright et al. [@CR217]). Reagents and conditions: (*i*) **91** (2 equiv) DMPA (0.2 equiv), CH~2~Cl~2~, 1 h, *h*ν 365 nm, 44%; (*ii*) **91** (5 equiv), DMPA (0.4 equiv), DTT (3 equiv), *h*ν 365 nm

The utility of direct lipidation was explored using more structurally complex antigenic peptide substrate derived from the cytomegalovirus ppUL85 protein (Kopycinski et al. [@CR111]) comprising an *N*-terminally CysSK~4~, motif Ac-CSKKKK-NLVPMVATV (**95**). Pleasingly, good conversion of **95** to *S*-palmitoylated peptide antigen **96** using the photoinitiated ' thiol-ene' reaction, **91** and optimized conditions (DMPA, DTT, DMSO) was observed as judged by RP HPLC profile (Scheme [9.14](#Sch14){ref-type="fig"}b) (Wright et al. [@CR216]; Wright et al. [@CR217]). We therefore coined the term 'Cysteine Lipidation on a Peptide or Amino acid (CLipPA)' to describe this efficient transformation allowing for one step lipidation of *N*α-protected cysteine derivatives using vinyl palmitate .

We subsequently focused on a detailed study to optimise conditions for highly selective and effective mono-*S*- palmitoylation of peptides using CLipPA technology (Yang et al. [@CR222]). Our first goal was to provide optimal conditions for the synthesis of a lipidated *N*α-protected cysteine building block that could be used directly in SPPS. The *N*α-protecting group, radical initiator and activation method were revised. Treatment of *N*α-protected Fmoc, Boc or *N*α-acetylated cysteine with an excess of vinyl palmitate in the presence of DMPA or 2,2-azo-bis(2-methylpropioniytile (AIBN) as radical initiator in either CH~2~Cl~2~ or 1,2-dichloroethane as solvent and under thermal heating (reflux at 90 °C), microwave irradiation (100 W, 70 °C) or UV light (365 nm) was studied. The *S*-palmitoylated products obtained were readily purified by silica gel chromatography without the need for RP HPLC.

An optimal conversion of *N*α-protected with Fmoc- or Boc cysteine **90** and **96** was observed under UV light activation, using excess DMPA (1 equiv) for 1 h in CH~2~Cl~2~ affording **92** and **97** in 85% yield (Scheme [9.15](#Sch15){ref-type="fig"}a). Heating, either conventional or using microwave, gave lower yields due to the premature cleavage of Fmoc protecting group and the instability of the Boc group to high temperatures. Conversely, lipidation of *N*α-Ac cysteine **98** appeared to be straightforward under all conditions tested giving good to excellent yields of the expected *N*α-Ac and *S*-palmitoylated product **99**. However the most effective conversion was when CH~2~Cl~2~ and AIBN were used under microwave heating (100 W, 70 °C) for 80 min leading to quantitative formation of desired product **99** (Scheme [9.15](#Sch15){ref-type="fig"}b) (Yang et al. [@CR222]).Scheme 9.15(**a**) Lipidation of Fmoc-Cys-OH (**90**) and Boc-Cys-OH **(96**) with vinyl palmitate (**91**) using optimized conditions for CLipPA; (**b**) Lipidation of Ac-Cys-OH (**98**) with vinyl palmitate (**91**) using optimized conditions for CLipPA; (**c**) On-resin lipidation of antigen **100** using *N*α-protected *S*-palmitoylated cysteine building blocks **92** and **99** (Wright et al. [@CR216]; Wright et al. [@CR217]; Yang et al. [@CR222]). Reagents and conditions: (*i*) **91** (1.5 equiv), DMPA (1 equiv), CH~2~Cl~2~, 1 h, *h*ν 365 nm, 85%; (*ii*) **91** (1.5 equiv), AIBN (1 equiv), CH~2~Cl~2~, 80 min, MW, 100 W, 70 °C, 99%; (*iii*) **92** or **99**, PyBOP, 2,4,6-trimethylcollidine, CH~2~Cl~2~/DMF (1:1), 1 h, rt; (*iv*) (for building block **92**): 20% piperidine in DMF, then 20% Ac~2~O in DMF; (*v*) TFA/3,6-dioxa-1,8-octane-dithiol (DODT)/H~2~O/*i*Pr~3~SiH (94:2.5:2.5:1, v/v/v/v)

The choice of *N*α-protecting group may influence the degree of racemization during the coupling step when SPPS is performed (Zhang et al. [@CR235]). Therefore, the coupling of *S*-palmitoylated, *N*α--protected building blocks, **92** or **99** to a model peptide sequence was evaluated (Kopycinski et al. [@CR111]). The Met residue of NLVPMVATV was substituted with Cys(*t*Bu) to demonstrate applicability of the ' thiol-ene' reaction conditions to a suitably protected cysteine thiol. The resin-bound and side-chain protected peptide H~2~N-S(*t*Bu)K(Boc)K(Boc)K(Boc)K(Boc)-N(Trt)LVPC(*t*Bu)VAT(*t*Bu)V-resin (**100**) was prepared using Fmoc SPPS at room temperature with HATU/*i*Pr~2~NEt and piperidine as coupling and Fmoc deprotection reagents and acylation with the lipidated building blocks, **92** or **99** was undertaken using racemization-suppressing conditions (PyBOP, 2,4,6-collidine, room temperature) (Zhang et al. [@CR235]; Carpino et al. [@CR29]; Carpino and El-Faham [@CR28]). In the case of *N*α-Fmoc-protected **92**, the Fmoc protecting group was removed after coupling and subsequently exchanged for an acetyl group before TFA-mediated peptide cleavage was performed affording **101** (Scheme [9.15](#Sch15){ref-type="fig"}c). This allowed for a direct comparison of RP HPLC profiles to assess the degree of racemization. The RP HPLC chromatogram investigation of crude **101**, obtained by using either **92** or **99** building block revealed that 1:1 ratio of epimers was formed when acetamide protecting group was used for lipidated cysteine incorporation. No detectable epimerization was however observed when *N*α-Fmoc-protected **92** was used for lipid incorporation. The type of *N*α-protecting group clearly influenced the degree of racemization during the study indicating the preferred choice of Fmoc-protected building block **92** for Fmoc SPPS-mediated peptide lipidation.

We then focused on reaction conditions that would allow direct lipidation of a thiol-containing peptide affording an *S*-palmitoylated construct **101** in a convergent-like approach.

The construct **102**, derived from resin-bound **100**, incorporated two cysteine residues; an *N*-terminal Cys with a sulfhydryl group ready for ' thiol-ene' conjugation and the side chain of the second, internally located cysteine was masked with *t*Bu. Subsequent photoinitiated lipidation at 365 nm of **102** using vinyl palmitate **91** (7 equiv) and previously reported conditions \[DMPA (0.5 equiv), DTT (3 equiv) in NMP for 60 min\] afforded *S*-palmitoylated peptide **101** albeit in variable yields (Scheme [9.16](#Sch16){ref-type="fig"}a) (Wright et al. [@CR216]; Wright et al. [@CR217]). A careful examination of LC-MS profiles of the ' thiol-ene' reaction leading to desired conjugate **101** identified formation of unwanted by-products such as DTT-adducts and bis-palmitoylated peptide **104**. The competitive formation of **104** by-product was found to increase with increasing levels of vinyl palmitate in the reaction mixture. Substitution of DTT with the more bulky mercaptan *tert*-butyl thiol (*t*BuSH) proved superior in suppressing an unwanted addition of the thiol scavenger to the carbon-centered radical **103**. Formation of undesired bis-palmitoylated adduct **104** was also diminished by including an organosilane-based coreductant (*i*Pr~3~SiH) that facilitated hydrogen transfer to the radical intermediate **103**. Furthermore, decreasing the pH of reaction mixture with TFA led to a cleaner reaction profile, presumably a result of protonation of electron-rich amine residues. Moreover, a large excess of vinyl palmitate (**91**), *tert*-butyl mercaptan and *i*Pr~3~SiH were also needed to maximise conversion of **102** to the desired **101**. Although a large excess of vinyl palmitate was used in the optimized, photoinitiated (*h*ν 365 nm) conditions \[**91** (70 equiv), DMPA (0.5 equiv), *t*BuSH (80 equiv), *i*Pr~3~SiH (80 equiv), TFA (5% v/v) in NMP for 30 min\], a now quantitative conversion of peptide **102** to the *S*-monopalmitoylated construct **101** (95%, based on the corresponding peak integration on the RP HPLC profile) was observed with negligible levels of bis-adduct **104** formed (Scheme [9.16](#Sch16){ref-type="fig"}b).Scheme 9.16CLipPA direct conjugation of vinyl palmitate (**91**) and semiprotected peptide **102** under unoptimised conditions (**a**) and optimized conditions (**b**) (Yang et al. [@CR222]). Reagents and conditions: (*i*) **91** (7 equiv), DMPA (0.5 equiv), DTT (3 equiv) NMP, 1 h, *h*ν 365 nm; (*ii*) **91** (70 equiv), DMPA (0.5 equiv), *t*BuSH (80 equiv), *i*Pr~3~SiH (80 equiv), TFA/NMP (5:95, v/v), 30 min, *h*ν 365 nm

The optimized CLipPA technology could be used to effect direct *S*-monopalmitoylation of complex, unprotected peptide substrates as demonstrated for long peptides including Ac-CSKKKK-GARGPESRLLEFYLAMPFATPMEAELARRSLAQDAPPL-OH and H~2~N-CSKKKK-VPGVLLKEFTVSGNILTIRLTAADHR-OH, derived from NY-ESO-1(79-116) and NY-ESO-1(118-143), respectively. An excellent conversion to the desired lipidated peptide **105** (81%) and good 46% conversion to **106**, based on RP HPLC profiles, demonstrated the power of this new strategy (Fig. [9.14](#Fig14){ref-type="fig"}) (Yang et al. [@CR222]).Fig. 9.14*S*-Palmitoylated long peptide products accessed using CLipPA technology (Yang et al. [@CR222])

The CLipPA technology offers a feasible one-step approach to lipidated peptide constructs containing all-natural bonds. We believe that this technique has strong potential to play a key role in self-adjuvanting peptide-based vaccine development in the future. The use of CLipPA eliminates the need for complex, multi-step and timeconsuming solution-phase synthesis of lipidated building blocks that are not readily available in all research laboratories. Depending on the vaccine construct requirements, either a stepwise SPPS approach, or a direct, convergent-like substrate lipidation can be executed using the 'thiol-ene' reaction and the optimized CLipPA conditions to afford S-palmitoylated assemblies in excellent yields with high selectivity.

Conclusions {#Sec13}
===========

Lipidation of peptides and proteins plays an important role in improving pharmacokinetic and pharmacodynamic profiles of peptides which may lead to potent analogues with clinical potential. Lipidated peptides activating TLR2 are crucial for peptide-based self-adjuvanting vaccine development. A simple, efficient and low-cost synthetic approach for incorporation of lipid motifs into peptides for subsequent bioevaluation is required. Synthesis of lipidated peptides *via* a standard SPPS technique using orthogonal protecting group strategy poses a challenge due to decreased solubility of lipopeptides. Novel synthetic advances such as the atom economical and functional group compatible CLipPA technique provides a useful approach to access *S*-palmitoylated peptides with a range of applications including vaccine design.
